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ABSTRACT 
Functional dyspepsia (FD) is believed to be caused by pathophysiological changes in 
the upper gut. Gastro-intestinal motility, epithelial transport and signalling is associated 
with the metabolism of nutrients and the complex regulation of hunger and satiety. 
Glucagon-like peptide 1 (GLP-1) and peptide YY (PYY) are considered “hot targets”. 
Both are anorexigenic, can induce nausea, and are involved in neuronal and hormonal 
feedback.  Epithelial transport and signalling are partly controlled by the action of the 
neurotransmitter serotonin (5-HT). 5-HT forms the “link” between luminal stimulation 
and the enteric nervous system. We aimed at investigating if GLP-1, PYY and 5-HT 
are involved in the pathogenesis of FD. 
 
In study I and II healthy subjects were given a radiolabelled omelette during 
intravenous infusion of saline, PYY1-36, or PYY3-36 (study I) and saline or the GLP-
1 receptor antagonist Exendin(9-39)amide (study II) in a single-blinded, randomized 
design. Gastric emptying (scintigraphy), appetite ratings (VAS), and plasma 
concentrations of insulin, glucose, GLP-1, PYY and glucagon were studied. In study 
III FD patients and controls consumed two liquid meals, first a fixed amount and then 
until maximal satiety. Gastric emptying (paracetamol absorption test) and plasma 
concentrations of GLP-1, glucose and insulin were assessed as well as appetite ratings 
and dyspeptic symptoms. In study IV duodenal mucosal biopsies from FD patients and 
controls were studied for the number of 5-HT-containing cells (immunohistochemistry) 
and the expression of different 5-HT receptors by means of PCR.  Biopsies were also 
mounted in Ussing chambers for evaluation of basal and 5-HT-stimulated short-circuit 
current. In study V duodenal biopsies from non-patients with FD and controls from a 
population based upper endoscopy study were evaluated immunohistochemically for 
Chromogranin A (CGA) as endocrine cell marker and 5-HT. Individuals with FD were 
further divided into epigastric pain syndrome (EPS) and postprandial distress syndrome 
(PDS).  
 
PYY3-36 and PYY1-36 inhibits gastric emptying (PYY3-36 most effectively), and 
decreased the postprandial rise in insulin. PYY3-36 induced nausea and decreased 
prospective consumption. GLP-1 was involved in regulation of postprandial gastric 
motility, in insulin and glucose levels, and restrained glucagon secretion. Gastric 
emptying was not affected and we conclude that GLP-1 has a role as incretin hormone 
independent of gastric emptying. FD patients had normal postprandial glucose and 
GLP-1 concentrations. The FD-EPS subgroup had higher postprandial insulin levels 
compared to controls. Exogenous 5-HT induced lower short-circuit current and higher 
electrical resistance in FD. FD patients had higher gene expression of HTR3E and 
SERT and lower expression of HTR7 and TPH1. The number of 5-HT containing cells 
in duodenal mucosa was similar in FD patients and controls, and adults with FD had 
less endocrine cells and a normal number of 5-HT containing cells compared to 
controls. Endocrine cells was significantly decreased in the duodenal bulb in EPS but 
not PDS.  
 
Our results provide new evidence that altered endocrine secretion in the small bowel is 
part of the disease mechanism in FD, with PYY and GLP-1 as key candidates. GLP-1 
specifically contributes to the development of nausea. Furthermore, FD patients have 
abnormal 5-HT stimulated electrolyte secretion in the duodenum with possible 
involvement of the 5-HT receptors 3E and 7. 
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1 BACKGROUND 
1.1 INTRODUCTION 
 
“The digestive canal represents a tube passing through the entire organism and 
communicating with the external world, i.e. as it were the external surface of the body, 
but turned inwards and thus hidden in the organism.”  
 
This quotation from Ivan P. Pavlov (1849-1936) captures a number of important 
aspects of gastrointestinal (GI) physiology: 
 
Firstly, the intestinal canal consists of a series of hollow organs, highly specialised and 
separated from each other by sphincters. They are accompanied by some accessory 
glands, which provide secretions to the “tube lumen”. This thesis focuses on the small 
bowel, where the pancreas is an accessory gland. The pathophysiology of the stomach 
is also included, as its functions are closely connected. The stomach acts as storage 
organ and also initiates digestion by shredding and semi-liquefying ingested food. 
During the gastric emptying process, the mass is pressed through the pyloric canal into 
the duodenum, where nutrient absorption takes place and metabolic processes are 
initiated, assisted by the action of the pancreatic gland. The distal small bowel 
continues the digestive process, re-absorbs fluids and regulates gastric and duodenal 
activity via feedback mechanisms. The following figure illustrates the upper digestive 
system including a macroscopic view of the duodenal wall. 
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Secondly, similar to the external area of our body, the GI lumen is subject to intense 
luminal stress. Intact mucosal function is ensured by a complex defence system. 
Communication with the external world as well as inter-intestinal communication and 
signals to the brain are facilitated by approximately 100 million neurons, which form 
the enteric nervous system (ENS). Apart from this “mini-brain”, GI function is 
regulated by hormonal communication to such an extent that the GI system can be 
described as the largest endocrine organ in the human body. A deeper understanding of 
this gut-brain-energy axis will hopefully lead to the development of treatment options 
for some of the more complex functional GI disorders, namely functional dyspepsia 
(FD) and the irritable bowel syndrome (IBS), but also for nausea, eating disorders and 
diabetic gastroparesis, for which no specific treatment exists at present.  
 
Thirdly, “the organ is hidden” which is especially true of the small bowel, as it is not 
easily accessed by endoscopic techniques (except for the proximal duodenum). This 
has contributed to the focus on stomach pathology in previous FD research as well as 
the paucity of studies on small bowel dysfunction. Most gut functions are autonomic 
and thus “hidden” from consciousness.   
 
Ivan Pavlov was awarded the Nobel Prize for Physiology or Medicine in 1904 “in 
recognition of his work on the physiology of digestion, through which knowledge on 
vital aspects of the subject has been transformed and enlarged”. 
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1.2 DIGESTION 
 
1.2.1 Cephalic phase and the role of the stomach 
The stomach is divided into four sections, as illustrated on the previous page. The 
epithelium consists of a single cell layer covered by protecting mucus and invaginated 
by gastric pits where glands are situated that contain mucus producing cells in the 
isthmus (“neck”) and endocrine cells in the base. Different exocrine and endocrine cell 
types are strategically placed within the different sections. Mucus secreting cells are, 
for example, situated in the cardia, fundus and pylorus, whilst acid secreting cells are 
found in the corpus.  
                                                                                 
Digestion starts with the cephalic phase, first described by I. Pavlov. During this phase, 
which is initiated by the sight, smell, taste and thought of food, an estimated 50% of 
gastro-intestinal secretion and a distinct change in motility pattern, mediated by vagal 
nerve activity, take place in order to prepare the system to receive food. In the stomach, 
receptive relaxation of the fundus begins during this phase, which is further described 
below. When food enters the stomach through the lower esophageal sphincter, the 
digestive process starts with activation of proteases (mainly pepsinogen, secreted by 
“chief cells” in the fundus) by the presence of hydrochloric acid. This acid is also part 
of the defence system against microbial invasion. Solid particles are churned into small 
pieces by muscular action in the corpus, as will be described below.  
 
Gastric acid components are secreted by parietal (oxyntic) cells in the corpus. These 
cells secrete hydrogen and hydronium ions through an active, energy-dependent pump 
system, which works against a concentration gradient. They are stimulated and 
inhibited by different mediators, including the hormones gastrin (acid stimulator, 
secreted when intra-gastric pH rises), gastric inhibitory peptide (GIP) and secretin (acid 
inhibitors, secreted from duodenal cells when gastric acid leaks into the duodenal 
lumen), and somatostatin (acid inhibitor, secreted from endocrine cells in the pylorus in 
response to low pH). Proton pump inhibitors (PPI) in drug form are used for the 
treatment of gastroesophageal reflux disease and gastric ulcer disease and are partially 
effective in dyspeptic patients, although their role in “true” FD is questionable.  
 
1.2.2 Gastric motility 
Gastric accommodation starts with receptive relaxation of the fundus, which begins 
during the cephalic phase and is triggered by mechanoreceptors in the oropharynx. A 
vagally mediated adaptive modulation of smooth muscle contractions in the proximal 
stomach leads to an increase in volume without increase of pressure. The process 
continues when food reaches the stomach until a threshold is reached, after which 
active dilatation of the fundus is necessary to further increase the volume. This 
phenomenon is called gastric accommodation and can be identified by an increase in 
intraluminal pressure. A similar reaction can be initiated by duodenal distension, as 
demonstrated by barostat studies. Accommodation does not take place to the same 
extent after vagotomy. The exact mechanisms are unclear and even if the vagus nerve 
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has a modulatory function, the enteric nervous system (ENS) is generally believed to be 
the primary regulator.  
 
Watery liquids pass through the stomach without delay and are emptied in an 
exponential pattern. Carbohydrate and fat rich liquids leave the stomach more slowly 
and a solid meal does not leave the stomach until it is reduced in size to less than 2 mm. 
This is achieved by mid-gastric corpus contractions together with the decomposing 
action of gastric acid and peptidases, followed by a process of repeated propulsion, 
grinding and retro-pulsion. The time that solid components remain in the stomach is 
known as the lag phase. A normal sized solid-liquid mixed meal has a lag-phase of 
approximately 60 minutes.  
 
Gastric emptying of solids occurs when the pulverised and liquefied material is 
propelled in small portions through the pylorus to the duodenum. Gastric emptying 
slows down as a result of inhibited antral motor activity, increased fundic relaxation, 
pyloric sphincter contractions and altered intestinal motility. Both in the proximal and 
the distal duodenum, receptors that sense pH, calorie amount, osmolarity and different 
nutrient types can, with the help of hormonal and neural mediators, activate feedback 
mechanisms that modulate the gastric emptying rate. In the duodenum, cholecystokinin 
(CCK) is the most important mediator and secretion is associated with a reduction in 
the desire to eat and a delay in gastric emptying. The “ileal brake” (see below) is 
another mechanism that results in inhibition of upper GI motility.  
  
Between meals, a different pattern of smooth muscle contraction originates in the 
stomach and continues through the small intestine to regularly “sweep out” luminal 
contents, called the migrating motor complex. Basal gastric tone is maintained through 
a balance between cholinergic (excitatory) and non-cholinergic (inhibitory, 
predominantly vagal) activity.  
 
1.2.3 Small bowel physiology 
Entry of gastric acid into the duodenum induces a neutralising process, in which the 
key player is secretin (produced in duodenal cells) that stimulates bicarbonate (HCO3-) 
and fluid secretion from pancreas. In addition to pancreatic HCO3-, the proximal 
duodenum also secretes HCO3- through a permeable epithelium that is held together by 
low-resistance tight junctions. 
 
In response to food in the lumen, hormones are released from endocrine cells in the 
duodenum and jejunum. These hormones have several effects including regulation of 
gastric empting and eating behaviour, the latter by reducing appetite and enhancing the 
sense of satiety and fullness. Satiety can be achieved, at least in part, by a reduction in 
gastric emptying. Exact hormone action mechanisms remain unclear, but secretion is 
associated with a modulation of vagal activity and effects on brain stem function, both 
via the vagal nerve system and hormones that are transported by the blood stream to 
stimulate receptors in the area postrema and hypothalamus. Features and function of 
glucagon-like peptide 1 (GLP-1) and peptide YY (PYY) are described below. 
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Furthermore, food carries a high antigen load, and a food intake-inhibiting role of 
cytokines produced in small bowel mucosa has been hypothesised. Moreover, some 
inflammatory mediators are known to modulate ENS function.  
 
Nutrient digestion and absorption mainly take place in the jejunum. Pancreatic enzymes 
catalyse the chemical digestion of nutrients upon CCK stimulation, after which they 
enter epithelial cells by diffusion. In order to increase the absorptive area, the 
duodenum is folded into the plicae circulares, villi and microvilli.  
 
Glucagon-like peptide 1 
GLP-1 is a cleavage product from pro-glucagon. The precursor is produced in the 
pancreas and in specialized endocrine cells in the ileum and caecum mucosa (L-cells). 
In contrast to pancreatic tissue, where pro-glucagon is mainly cleaved into glucagon 
(and glycentin related pancreatic polypeptide), intestinal cells produce glycentin, GLP-
1 and GLP-2. Secretion of GLP-1 is highly stimulated by luminal carbohydrates and 
lipids, as well as by some neuropeptides (e.g. Substance P). GLP-1 itself strongly 
induces a number of biological responses, which is a reason why the hormone has 
gained increased attention in different branches of GI research [1].  
 
GLP-1 is probably best known for enhancing pancreatic insulin secretion and 
suppressing glucagon in a glucose dependent manner (only effective when glucose 
concentrations are high). Furthermore, GLP-1 appears to restore pancreatic glucose 
sensitivity and to stimulate proliferation of insulin-secreting cells. GLP-1 analogues as 
treatment for Type II Diabetes have already entered the Swedish market. In the GI tract, 
GLP-1 secretion leads to inhibition of gastric acid secretion and affects gastric motility, 
the latter indicating that GLP-1 participates in the “ileal brake”. More specifically, 
GLP-1 alters the motility pattern by relaxing the muscular layers in the antrum and 
duodenum at the same time as the pyloric tone increases. Vagal afferent and efferent 
nerve signalling is part of the process. Another GLP-1 mediated effect is the reduction 
of food intake, which can be seen in subjects who receive intravenous GLP-1 infusions 
at physiological doses.   
 
The GLP-1 receptor is highly GLP-1 selective with only low affinity for glucagon and 
GIP. The G-protein coupled receptor is a member of the glucagon receptor family and a 
membrane protein, which possesses seven membrane-spanning domains, organised in a 
ligand specific three-dimensional structure. In the inactive state, a G-protein is coupled 
to the intracellular end of the helix, which detaches upon receptor stimulation and 
induces intracellular responses via second messenger actions. 
 
Peptide YY 
PYY is co-localised with GLP-1 in endocrine cells, its structure is closely related to 
pancreatic polypeptide and, although more common in the large bowel, it is present 
throughout the entire GI canal. PYY3-36 is the most abundant of two biologically 
active isoforms (full-length PYY1-36 and N-terminally truncated PYY3-36) and best 
known for a pronounced anorectic effect [2, 3]. Nausea and a sense of fullness are the 
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dose-limiting side effects of the peptide. PYY1-36 has previously been shown to slow 
gastric emptying and inhibit intestinal fluid as well as electrolyte secretion [4, 5]. PYY 
is therefore considered an “ileal and colonic brake” mediator. Both isoforms seem to 
participate in modulation of insulin secretion. After subcutaneous administration of 
peptide analogues, the postprandial serum level of insulin increases both in the case of 
PYY1-36 and PYY3-36 [6]. 
 
PPY acts through neuropeptide Y receptors, which are G-protein coupled receptors that 
respond to PYY isoforms, pancreatic polypeptide and neuropeptide Y. There are five 
mammalian neuropeptide Y receptors, designated Y1 to Y5. PYY3-36 selectively 
works through the Y2 receptor, while PYY1-36 targets the Y1, Y2 and Y5 receptors 
[7].  
 
Ileal brake 
The ileal brake can be described as a feedback mechanism that optimises absorption of 
luminal nutrients and is initiated when nutrients reach the distal parts of the small 
bowel. The process includes delayed gastric emptying and GI transit, relaxation of 
gastric and duodenal motility, decreased number of contractions in jejunal motility as 
well as reduced pancreatic enzyme, biliary and gastric acid secretion. The process is 
accompanied by a decrease in the sensation of hunger, less food intake and increased 
satiety. It has been suggested that the satiety increasing effect is a consequence of 
delayed gastric emptying. Activation of neural afferents as well as hormone release 
from intestinal epithelial cells has been shown to mediate the described effects, but the 
exact mechanisms are unclear. Apart from GLP-1 and PYY, which are considered “key 
candidate mediators”, also neurotensin, oxyntomodulin and various other 
neurotransmitters have been suggested to be involved.  
 
 
1.3 GLUCOSE METABOLISM 
 
1.3.1 Pancreatic function 
The pancreas is a multi-function gland with both endocrine and exocrine roles. The 
pancreatic fluid secreted to the duodenum is produced in acinar cells, which are 
connected to ducts and can be stimulated directly by hormones produced in adjacent 
endocrine cells, or by ENS signals. Four different endocrine cells, primarily secreting 
glucagon, insulin, somatostatin and pancreatic polypeptide, are localised close to blood 
vessels in the so-called islets of Langerhans. Their primary physiological role is the 
regulation of blood glucose levels and glucose metabolism, although they all seem to 
be involved in digestion and eating behaviour control. Pancreatic polypeptide, for 
example, has been shown to stimulate gastric acid secretion, inhibit exocrine pancreatic 
secretion, and slow gastric emptying and reduce food intake via vagal nerve action [8-
11]. The primary regulators of glucose homeostasis are glucagon and insulin. Glucose 
itself is believed to play a role in eating behaviour, because food intake is preceded by a 
decrease in serum glucose concentrations. High glucose levels after nutrient absorption 
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trigger insulin secretion, and insulin has been hypothesised to be involved in appetite 
regulation. 
 
Insulin 
Insulin producing cells constitute 65-80% of all endocrine cells in the pancreas. The 
hormone is derived from precursor pre-pro-insulin by two cleaving steps and structured 
as a dimer of two protein chains linked together by disulphide bonds. This three 
dimensional conformation is very similar among species, and any vertebrate-derived 
insulin is likely to be biologically active in humans. Insulin is stored in secretory 
vesicles and rapidly released in the presence of glucose in serum by a glucose-
transporter coupled process. Independent of glucose levels, secretion can also be 
stimulated by CCK, GLP-1, GIP and vagus nerve action. Insulin allows glucose to be 
taken up by the liver, skeletal muscle and adipose tissue, which are primary sites of 
glucose metabolism and storage. In diabetes, insulin secretion is impaired or target cells 
are insulin resistant. 
 
Glucagon 
Glucagon is released from pancreatic cells during hypoglycemia and acts primarily on 
glucagon receptors in liver cells, in which glucose is stored in form of glycogen. 
Activation of the glucagon receptor starts glycogenolysis and gluconeogenesis, which 
lead to a rapid rise in serum glucose levels. Glucagon injections are used in emergency 
situations to correct hypoglycemia. Insulin inhibits the release and degradation of 
glucagon.  
 
 
1.4 EPITHELIAL SENSING & THE SEROTONIN NEUROTRANSMITTER 
 
Epithelial secretion in the small bowel is regulated by sensory neurons via intrinsic 
afferent neurons (local afferents) and extrinsic afferent neurons (vagal and spinal 
pathways), which are part of the ENS. These neurons are activated upon stimulation of 
strategically positioned entero-endocrine and mast cells in the mucosa, which respond 
to osmolarity changes, different composition of nutrients, mechanical distortion, drugs 
or bacterial products, etc. Distribution and content of the entero-endocrine cells differ 
between species and various parts of the GI tract.  
 
The duodenum has a high content of enterochromaffin (EC) cells, which have both an 
endocrine and neuro-endocrine function, as well as being the main site of serotonin (5-
hydroxytryptamine, 5-HT) biosynthesis. The luminal stimulus for the release of 5-HT is 
mainly mechanical. The pressure that a food bolus exerts on the intestinal wall can 
activate EC cells either directly or indirectly via submucosal mechanosensors. 5-HT 
plasma levels are further raised in response to intraluminal pH changes, the presence of 
bile acid or luminal glucose. Alterations in the 5-HT related intestinal glucose sensing 
system and in EC cell function have been observed in diabetic mice [12]. An altered 
EC cell number has also been described in FD [13, 14].  
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Following secretion, 5-HT exerts its effect on 5-HT receptors (HTR), of which fourteen 
have been characterised to date. The following are expressed in the GI canal: HTR1A, 
1B, 1P, 2A, 2B, 3, 4 and 7. With the exception of HTR3, all are G-protein coupled 
receptors. HTR3 is a ligand-gated ion channel. Excitatory ENS receptors include 
HTR1P, 3 and 4, while the only inhibitory receptor is HTR1A. HTR3 and 4 can also be 
epithelial, i.e. non-neuronal, in nature. HTR2A is also an epithelial receptor, which can 
be directly activated by luminal stimuli. The figure below illustrates the organisation of 
the ENS with localisation of various 5-HT receptors in the intestinal wall. Information 
from afferent sensory neurons is passed to the submucosal and myenteric plexus of the 
ENS by a number of different pathways. Several pharmacological agents targeting 5-
HT receptors have been developed. HTR3 antagonists relieve nausea and can be 
symptom relieving in FD symptoms. HTR4 agonists affect intestinal motility while 
HTR2C agonists are used as weight-loss drugs.  
 
 
 
 
 
 
Exogenous 5-HT strongly stimulates epithelial secretion of electrolytes and fluids. In-
vitro, the effect is highest when 5-HT is added to the serosal as opposed to the mucosal 
side of an epithelial sheet [15]. In-vitro studies have further demonstrated that secretion 
in the duodenum is electrogenic and probably composed of chloride ions (Cl-) and 
HCO3- [16]. In the jejunum and ileum, Cl- secretion and sodium ion absorption account 
for most of the 5-HT stimulated ion transport [17].  
 
Tryptophan hydroxylase (TPH) is the rate-limiting enzyme in the biosynthesis of 5-HT. 
A tryptophan-amino acid free diet slows gastric emptying in healthy subjects and alters 
visceral pain perception. Increased transcription of isoform TPH1 has been described 
throughout the gut in female patients with isolated FD [18].  
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The serotonin plasma membrane transport protein (SERT) transports the highly 
charged 5-HT molecule over the lipid-bilayers of cell membranes, thereby regulating 5-
HT bioavailability. Pharmacological agents that inhibit SERT function also increase 5-
HT serum levels. SERT malfunction has been found to result in abdominal pain and 
diarrhoea [19]. A relationship between SERT gene alterations and FD has been 
suggested [20, 21].  
 
 
1.5 FUNCTIONAL DYSPEPSIA 
 
1.5.1 Definition and epidemiology 
 
FD is characterised by gastro-duodenal symptoms that cannot be explained by organic, 
systemic or metabolic disease. The main symptoms include epigastric pain, epigastric 
burning, bothersome postprandial bloating and early satiety. Descriptive definitions of 
individual symptoms have been presented by the Rome consensus committee, which 
also defined the diagnostic criteria that constitute the international standard in both 
research and clinical practice today [22]. Other common symptoms, although not stated 
among the Rome III diagnostic criteria, include nausea, vomiting, belching and weight 
loss.  
 
There are two FD sub-groups, defined by the dominant symptom profile: Postprandial 
Distress Syndrome (PDS), characterised by postprandial bloating and early satiety and 
Epigastric Pain Syndrome (EPS), characterised by epigastric pain or burning.  
 
Since almost all human beings can develop occasional dyspeptic symptoms, especially 
after acute intestinal infection, it is difficult to collect FD epidemiological data. 
Furthermore, there is a significant overlap with IBS and other functional intestinal 
disorders. Symptoms can vary over time to such a degree that the diagnosis may have 
to be changed. 
 
The prevalence of dyspepsia is 11-29%, depending on the definition [23, 24]. It is 
unclear whether or not there is a gender difference, although more women than men 
seek medical care for dyspeptic symptoms [25]. In the primary care setting, dyspepsia 
is common and rarely severe, and these patients not always have any investigation. The 
natural course of FD is not well known. In a Swedish study 13% of patients with un-
investigated dyspepsia are symptom-free after 1 year and 17% after 7 years [26].  
 
The subdivision into EPS and PDS was evaluated in the large population-based 
epidemiological Kalixanda study, data from which were used in Study V. Data were 
collected by means of a comprehensive questionnaire on different gastro-duodenal 
symptoms and upper endoscopic biopsies. Dyspeptic symptoms were found in 20% of 
the participants, who were representative of the Swedish national average. The 
prevalence of PDS was 12.2% and EPS 5.2%, with a minor overlap of 1.7% [27].  
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Epidemiological studies have indicated a correlation between FD, psychosocial factors 
and psychiatric disorders, especially anxiety and depression [27, 28]. So far, there is 
little evidence of a pathophysiological role in these disorders, but it is known that 
patients with psychological co-morbidity are more prone to seek health care [29]. Stress 
and emotional factors can also increase symptoms. Recent results from functional brain 
imaging studies suggest alterations in the interaction of gut-brain signals with signals 
from other brain related systems, including affective and cognitive circuits [30]. 
 
 
1.5.2 Disease mechanisms 
 
The mechanisms behind FD are unclear. Experts generally believe that symptoms are 
due to a combination of causes. The term FD could also comprise a number of separate 
diseases.  
 
Neither Helicobacter pylori (HP) nor altered secretion of gastric acid seems to be of 
significance in FD, whereas duodenal hypersensitivity to acid might be of importance 
[31]. In clinical practice HP and acid secretion are nevertheless important, because of 
the overlap between FD and acid and/or HP-related organic disease. 
 
Pathophysiological changes described include delayed emptying of the stomach, which 
is seen in 20-40% of FD patients [32-34], and impaired accommodation of the stomach, 
reported in about one third of patients. The significance of these findings is unclear. It 
has been suggested that early satiety is a consequence of impaired accommodation [35]. 
Postprandial fullness and vomiting are more common in connection with delayed 
emptying of solids [33].  
 
Visceral hypersensitivity is another pathophysiological finding, but is difficult to 
measure. In a Belgian study, 34% of FD patients had higher sensitivity to distension of 
the stomach, as measured by the barostat technique [36].  
 
In the same way as IBS, FD can start after an acute intestinal infection. According to a 
large Belgian study [37] 17% of FD patients have an acute, presumed postinfectious 
onset of their symptoms, together with a high record of weight loss, early satiety and 
nausea, as well as impaired accommodation.  
Recent studies show an interaction of mast cells, eosinophils and ECs [38-40]. Both 
eosinophils and mast cells are prevalent in duodenal mucosa and the former usually 
activate the latter during immune reactions. In IBS mast cell action is associated with 
the activation of enteric nerves [41]. Mast cells are also a significant source of 5-HT, 
which simulates receptors in the epithelium and on local, vagal and spinal nerve 
endings. A Chinese study recently revealed a higher level of ECs and 5-HT secretion in 
gastric mucosa in FD patients [14]. Eosinophils have been found to be present and de-
granulated in FD, where they are related to dyspeptic symptoms and altered gastric 
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motility [42, 43]. In immune activation in the mucosa, mast cells and eosinophils also 
interact with T-lymphocytes [44]. The number of intraepithelial lymphocytes was 
studied in the duodenum of FD patients, but no difference was observed compared to 
healthy controls [43].  
In addition to 5-HT, numerous other mediators are secreted by the intestinal wall in 
response to meal intake and transported by the circulatory system to target cells, where 
they initiate actions that regulate both motor and sensory functions. Upper gut 
mediators that might be of importance in FD pathophysiology include gastrin, which is 
secreted by gastric fundus cells, CCK and leptin, which are mainly secreted by the 
duodenal epithelium, as well as PYY and GLP-1, which are secreted by cells in the 
distal small bowel. Ghrelin is another candidate mediator, released during a fasting 
state, which has been shown to effectively accelerate gastric emptying and to be 
elevated in plasma in dysmotility-like FD. Ghrelin receptor agonists have been 
proposed as a novel treatment for FD and diabetic gastroparesis [45].  
 
Gastrin stimulates gastric acid secretion and is involved in gastric emptying. Elevated 
plasma levels have been found in FD patients [46], but were not associated with 
symptoms. CCK acts on receptors situated in the gastric mucosa (CCK2), vagal nerve 
terminals (CCK1) and the brain (CCK1), and is highly involved in gastric motility 
mechanisms and eating behaviour [47]. Several studies have supported a role of CCK 
in FD. Intravenous administration of the CCK analogue CCK-8 can induce dyspeptic 
symptoms [48]. Leptin stimulates mucin secretion, reduces appetite and activates vagal 
afferents. Elevated leptin plasma levels have been observed in dysmotility-like FD [49]. 
Both PYY and GLP-1 affect food intake and can induce nausea. They are believed to 
be part of the ileal brake and, in the case of GLP-1, vagal nerve stimulation takes place 
[50]. Furthermore, GLP-1 is an incretin hormone and thus involved in glucose 
metabolism. PYY inhibits fluid and electrolyte secretion. The role of PYY and GLP-1 
in the pathogenesis of FD has not yet been evaluated.  
 
Several of the entero-hormones discussed above are involved in vagal signalling, and it 
has been suggested that neuro-hormonal signalling between the ENS and CNS is 
impaired in FD [51]. It can be hypothesised that there is a correlation between a 
dysfunctional gut-brain-axis and psychological co-morbidity. New techniques, e.g. 
functional brain imaging, can facilitate further investigation of the gut-brain-axis. 
Aspects that merit greater attention include primary ENS changes, such as local 
inflammation or impaired intrinsic signalling, where 5-HT seems to be a key target [40, 
52].  
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2 AIMS 
The general aim was to increase knowledge of small bowel function and its role in 
the pathophysiology of Functional Dyspepsia (FD) by studying the effect of 
hormones and neurotransmitters on gastric motility, duodenal epithelial function 
and pancreatic secretion and relating the findings to symptoms and metabolic 
control in patients. 
 
 
The specific aims were: 
 
Study I  
Does intravenous administration of PYY1-36 and PYY3-36 affect the gastric emptying 
rate or short-term metabolic control (glucose, insulin and GLP-1 levels) in healthy 
subjects? Do exogenous PYY1-36 and PYY3-36 affect appetite or satiety parameters?
       
Study II 
What is the role of endogenous GLP-1 in intra-gastric distribution and gastric emptying 
of a solid meal in healthy subjects? To what extent does endogenous GLP-1 affect 
postprandial insulin, glucagon, glucose and PYY levels? Does endogenous GLP-1 
influence appetite or satiety parameters? 
      
Study III  
Do FD patients have a different post-prandial secretion of glucose, insulin or GLP-1 
compared to healthy controls? Is there a correlation between dyspeptic symptoms and 
GLP-1 secretion?  
 
Study IV 
Is 5-HT-induced duodenal epithelial ion transport altered in FD patients? Do these 
patients have a different expression of 5-HT receptors or number of 5-HT expressing 
cells in the duodenum?  
 
Study V 
Does the number of duodenal endocrine cells and specifically the relative content of 5-
HT-containing endocrine cells differ between individuals with FD and controls? Is 
there a relationship to FD sub-types? 
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3 METHODS 
3.1 DUODENAL CELL PHYSIOLOGY 
Histological techniques 
Histological techniques, which involve the use of a microscope to study tissue samples, 
have played a central role in academic research since the 19th century. In 1906, the 
Nobel Prize in Medicine was awarded to histologists and medical doctors Camillo 
Golgi (1843-1926) and Santiago Ramon y Cajal (1852-1934). Histopathology, which 
examines manifestations of disease, is still an important tool in clinical practice. The 
tradition, feasibility and applicability of the technique means that material and expert 
help are usually easily accessible, standard protocols exist, results can be compared 
with other studies and the technique can be applied for different purposes. In 
immunohistochemistry (IHC) for example, peptides are stained with very high 
specificity, which can provide the researcher with an idea not only of the localization of 
the peptide in the cell or tissue complex, but also of the extent of peptide formation.   
 
In studies IV and V, fresh biopsies were fixated in formaldehyde, embedded in 
paraffin after 24 hours and later cut into 10 µm (study IV) and 3 µm (study V) sections.  
In histopathological evaluation, a standard combination of two stains is usually applied; 
the principal stain visualises the structure of interest, while the counterstain makes the 
principal stain more visible and also serves as a control.  
 
In study V, we stained with haematoxylin and eosin. The latter is an acidic dye, which 
binds to basic parts of the cell, such as the cytoplasm, while haematoxylin is a basic dye 
that can be found in acidic parts, such as the nucleus with its high concentration of 
nucleic acids (DNA and RNA).  
 
In study IV, we stained with haematoxylin and periodic acid-Schiff. Periodic acid 
reacts with certain carbohydrate macromolecules in a cell and forms aldehydes, which, 
in reaction with the Schiff reagent, produce a purple colour. Carbohydrate rich parts of 
the cell include connective tissue and mucus. Haematoxylin was used as a counterstain.  
 
When we evaluated a biopsy for possible pathology, we recorded the overall 
appearance, specifically the architecture of the villi, and the presence of possible acute 
and chronic inflammation (in form of inflammatory cells). We also assessed mucosal 
damage, especially edge damage, which results from squeezing the biopsy during 
endoscopy or mounting, and rated it with a severity score from 0-3.  
 
Immunohistochemistry 
We used immunostaining to detect 5-HT in studies IV and V and chromogranin A 
(CGA) as marker for endocrine cells in study V. Immunostaining is the process by 
which an antibody is directed against an antigen of interest, forming an antibody-
antigen complex that can be highly specific. A “label” or “tag” then identifies the 
complex. The labelling molecule might be a fluorophore, which is detected using a 
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fluorescence microscope, or the horseradish peroxidase enzyme, which induces a 
distinct dark colour change due to a chemical reaction.  
 
Study IV: Sections of 5 µM were deparaffinised and incubated with anti-5-HT (the 
primary layer) for 18 hours. The immunoreactions were visualised by means of 
biotinylated rabbit anti-mouse immunoglobulin (a universal antibody that recognises 
immunoglobulin G chains) as the second layer, followed by streptavidin-peroxidase 
complex as the third. Streptavidin binds very strongly to biotin in the biotinylated 
antibody, and peroxidase is the labelling molecule, which in this case induced a colour 
change by oxidising subsequently added diaminobenzidine (DAB). The process is 
illustrated in the figure below. Sections were counterstained with haematoxylin. A 
limitation of this method is the fact that endogenous biotin can lead to significant 
background staining.  
 
 
 
Study V: 3 µM sections underwent automated IHC with a Leica Bond Max system. 
This system works on the same principle as conventional IHC, starting with 
deparaffinisation of the sections, followed by incubation with either anti-5-HT or anti-
CGA and finally the application of an advanced dextran polymer technique to tag the 
antibody-antigen complex. In this technique, complexes are bound to a polymer 
backbone, to which different enzymes and antibodies (provided by the manufacturer) 
are conjugated. Any non-specific background staining is thus significantly reduced. 
Procedures were standardised according to local protocols. Haematoxylin was used as 
counterstain.  
 
5-HT stained cells can be quantified in different ways, e.g. as the number of stained 
cells per one hundred epithelial cells, the number of stained cells per high power field 
(HPF) or the number of stained cells per mm2. The total stained area per HPF or 
staining intensity might also be of interest.  
 
In study IV, the microscope was fitted with a camera and cells were counted from 
photomicrographs using the Image-Pro Plus 6.0 program, which makes it possible to 
determine both the number of stained cells and the stained area per HPF in an objective 
manner. We also determined the total stained area to obtain an idea of secretion 
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capacity independent of the number of 5-HT secreting cells. A field magnified 10 times 
was suitable for covering the biopsy area. 
 
In study V, stained cells were counted directly in the light microscope. In order to 
facilitate comparison with other studies, we decided to determine the number of cells 
per mm2. A field magnified 40 times was adequate for covering the sample area. 
Photographs were taken separately using a microscope equipped with a camera lens as 
well as Image J software in order to facilitate examination of the same regions for the 
two different stains and be able to compare as well as re-evaluate certain areas. In 
future studies, double-staining that co-localises CGA and another antigen of interest (5-
HT, PYY, GLP-1) might be an alternative.  
 
Polymerase chain reaction 
One of the most commonly applied techniques in molecular biology is the Polymerase 
chain reaction (PCR), which was developed by Kary Mullis (1944-1983) for which he 
was awarded the Nobel Prize in Chemistry in 1993 (shared with Michael Smith). The 
concept of PCR lies in the amplification of a few copies of a DNA sequence to 
thousands of copies, which can be detected and quantified. Its name is derived from 
DNA polymerase, the DNA replicating enzyme, which selectively replicates the target 
region with the help of primers (short DNA fragments containing sequences that are 
complementary to the target sequence). The method itself is based on cycles of repeated 
heating for DNA melting and cooling to allow enzymatic reaction and can roughly be 
divided into the following stages: 
 
1. At every cycle, the amount of product is doubled (assuming 100% reaction 
efficiency), which leads to exponential amplification. 
2. The reaction slows down as reagents are consumed and the enzyme DNA 
polymerase activity reduces. 
3. No more production occurs. To check whether the anticipated DNA fragment 
was generated, agarose gel electrophoresis is employed for size separation of 
the products, which are compared with DNA fragments of known size.  
 
Over the years, traditional PCR has advanced from detection at the end-point of the 
reaction to detection while the reaction is in progress, which enables more accurate 
DNA and RNA quantification and does not require post-PCR methods. There is usually 
some confusion about the term real-time PCR, which refers to a quantitative PCR 
technique that uses fluorescent dyes to detect the reaction product (or even a sequence-
specific DNA probe) at the end of each cycle, “in real time”. It is only during the 
exponential phase of the PCR reaction that it is possible to extrapolate backwards to 
determine the amount of starting template. The abbreviation of Real-time PCR is qPCR 
and not, as often believed, RT-PCR, which refers to the technique of reverse 
transcriptase PCR. RT-PCR qualitatively detects gene expression through the creation 
of complementary DNA transcripts from RNA.  
 
The two techniques can be combined to provide quantification of RNA. The combined 
assay, abbreviated as qRT-PCR or RT-qPCR, is currently the most powerful, sensitive 
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and quantitative assay for detection of RNA levels in human tissue and used in the 
clinical setting to identify diseases by their expression patterns as well as to perform 
expression analysis of single or multiple genes. In accordance with our hypothesis, we 
were interested in analysing the tissue for 5-HT receptor genes, the SERT gene 
SLC6A4 and the TPH1 gene, thus used qRT-PCR to perform expression analysis. 
 
In study IV, total RNA was extracted from duodenal biopsies and cDNA synthesised 
from it using commercially available kits. The quantitative RT-PCR process was 
automatised and performed separately for each gene; we employed an ABI Prism 7500 
Sequence Detection System in combination with specific TaqMan Gene Expression 
Assays according to the manufacturer’s instructions. The TaqMan is a probe that 
generates a fluorescent signal. In order to compare samples, a signal threshold is 
determined, which is the point during the exponential phase where all samples can be 
compared. The threshold is defined as the point at which the generated signal exceeds 
any background fluorescence. The fractional number of PCR cycles required for the 
level of fluoresence to exceed the threshold is defined as the cycle threshold (Ct). Ct 
values are directly proportional to the amount of starting template, and mRNA 
expression levels can be calculated from these values. The following figure shows a re-
construction of the Ct-plot from our study, including the actual Ct-values. 
 
 
 
 
3.2 DUODENAL EPITHELIAL FUNCTION  
Ussing chamber 
An Ussing chamber consists of two halves, between which a layer of epithelial tissue is 
placed. The polarised epithelium has the mucosal and the serosal side exposed to each 
half of the assembled chamber. Ion transport, which occurs across the epithelium, 
produces a potential difference (the voltage difference), which can be measured using 
two agar-bridges close to the tissue. Two current electrodes placed at a distance from 
the tissue are then used to cancel out the voltage difference. With no external, 
transmural difference in ion concentrations, the amount of current needed to eliminate a 
potential difference is defined as short-circuit current (SCC) and is the exact measure of 
an active net ion transport across the epithelium. The Danish scientist Hans H. Ussing 
(1911-2000) invented this technique in 1951 to study transport mechanisms across frog 
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skin. In study IV we used a modified version of his chamber system to study 5-HT 
stimulated epithelial transport.  
 
There have been few Ussing chamber studies on human GI tissue because of the 
limited availability of adequately sized tissue samples. Several miniaturised Ussing 
chamber systems have been developed, but increased edge damage, often as a result of 
squeezing of tissue, reduced tissue area due to employment of tissue glue, has probably 
limited their use. Niels Bindslev and his research group at the Panum Institute in 
Copenhagen designed a chamber that utilises air suction for mounting biopsies, known 
as the modified Ussing air suction (MUAS) chamber.  
 
Endoscopic biopsies are fixed in a central hole through two sandwiched discs by steady 
suction applied at one edge of the hole, leaving 5 mm2 of the biopsy exposed. The 
assembled discs with the mounted biopsy are inserted between two ordinary half-
chambers. 10 mL Krebs-Ringer-HCO3--buffer solution aerated with a CO2 containing 
gas in either half-chamber, maintains the pH and provides the cells with water and 
essential inorganic ions. Circulation is provided by gas-lift, and the temperature is 
maintained at 37 °C by water jackets. An automated voltage-clamp apparatus, adjusted 
to be sensitive to small signals, measures SCC and slope conductance from four units 
every 2 seconds when the clamp is on. Tips of agar bridges are inserted into the half-
chambers for measurement of potential differences and platinum electrodes for current 
injection.  
 
In study IV, 10 mm d-glucose was added to the serosal side solution to provide the 
necessary “fuel” for transport and tissue viability and 10 mm d-sorbitol to the mucosal 
side solution for osmotic balance. Both sides were gassed with 95% O2 and 5% CO2. 
 
Suction 
37 C water 
95 % O2  5 % CO2 
Drugs Drugs 
Bicarbonate 
Ringer 
I 
V
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Agar 
Bridge 
Ag-AgCl 
Electrode  
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The Bindslev group has developed a number of protocols for both absorptive and 
secretory processes, which can be used when designing control experiments or 
evaluating the viability and transport capacity of mounted tissue. Absorptive processes 
can be studied by applying different sugars to the mucosal bathing solution in 
increasing doses, followed by a single dose of an inhibitor. Secretory processes can be 
investigated by adding stimulating substances, such as 5-HT, to the serosal bathing 
solution. The dose-response relationship between increased concentrations of 5-HT in 
the solution and SCC can be analysed by non-linear fitting of parameters in the 
Michaelis-Menten or Hill equation.  
 
In study IV, after corrections for the solution resistance between the tips of the agar-
bridges, each experiment began with documentation of baseline values for SCC, 
conductance and potential difference, which correspond to basal active ion transport in 
the biopsy. 5-HT was then applied in cumulative doses with 5-min intervals between 
applications. The resulting concentration in the bathing solution ranged from 3 to 243 
µmol/L. D-Glucose, 5 mM, was later added to the mucosal side to test for tissue 
viability.  
The Ussing chamber method can also be used to determine which 5-HT receptor 
subtypes are functionally involved in the process, as described by Engelmann et al. 
[16]. In that particular study, different 5-HT receptor antagonists were added after a 
single 5-HT dose in the plateau phase of the 5-HT response. Suitable chemicals are 
commercially available for several of the 5-HT receptors that are relevant in the context 
of functional intestinal disease, e.g. ketanserin (HTR2 antagonist) and ondansetron 
(HTR3 antagonist). 
 
 
 
The “real” set-up 
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3.3 THE ENDOCRINE SYSTEM 
Manipulating hormone action 
Hormones are mediators released from endocrine tissue into the bloodstream where 
they are transported to target tissue and generate a physiological response, either by 
interaction with specific receptors on the surface of their target cell or by binding an 
intracellular receptor in the cell cytoplasm. Intravenous infusion can ensure the full 
bioavailability of any endocrine substance over time and is therefore commonly used to 
study their effect. Infused quantities are calculated to correspond with either 
physiological or pharmacological plasma levels, which are normally determined based 
on previous studies. Receptor inhibitors can be used to further examine the nature and 
extent of the physiological action.  
 
In study I, we compared the effects of PYY1-36 with the truncated form PYY3-36 on 
gastric motility, hormone secretion and satiety mechanisms. Both forms are 
physiologically active in the human body, but their specific roles are still unclear. 
Subjects received intravenous infusions of either 0.8 pmol kg-1 min-1 synthetic human 
PYY1-36 or PYY3-36 dissolved in 0.9 % saline solution containing 0.1 % albumin, or 
a saline solution containing albumin alone, via an indwelling catheter placed in one 
antecubital vein. Infusions were started simultaneously with intake of a radiolabelled 
omelette (that was consumed within 10 min) and continued for 180 min. Total PYY 
levels were measured in serum at the same time as scintigraphic measurements (to 
study gastric motility) and the basal PYY level, maximal concentration and its stability 
were documented.  
 
Circulating GLP-1 in the blood stream is rapidly inactivated by the enzyme dipeptidyl 
peptidase-4 (DDP-4). A common way to study the endogenous actions of GLP-1 is by 
means of DDP-4 inhibitors, which block GLP-1 degradation, thereby enhancing its 
endogenous action. However, DDP-4 degrades not only GLP-1 but also the incretin 
hormone GIP, while plasma concentrations for both hormones are increased. We chose 
to study the role of endogenous GLP-1 using a specific competitive antagonist of the 
GLP-1 receptor, called Exendin(9-39)amide, Ex(9-39). Ex(9-39) is a truncated form of 
the non-mammalian exendin-4 peptide, which shares some sequence homology with 
GLP-1 and has a similar affinity to the GLP-1 receptor, and a sufficient dose can block 
receptor activity.   
 
In study II, subjects received an intravenous infusion of either 300 pmolkg-1min-1 
Ex(9-39) dissolved in a 0.9 % saline solution containing 0.1 % albumin or a saline 
solution only containing albumin. Infusions were started 50 min before food intake and 
continued for a total of 240 min. Gastric motility, hormone secretion and satiety 
mechanisms were studied. 
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Radioimmunoassay 
The Radioimmunoassay (RIA) is a method that allows very precise measurements of 
hormone levels in blood samples. This revolutionary technique was developed by 
Rosalyn Yalow (1921-2011) and Solomon Aaron Berson (1918-1972) and in 1977 Dr. 
Yalow received the Nobel Prize in Medicine specifically for the insulin assay.  
 
In the RIA a tracer, which is a radioactive labelled antigen (corresponding to the 
peptide that we intend to measure), is added to a solution with a known amount of 
antibody for that antigen. The solution is mixed with a sample of patient plasma, which 
contains an unknown amount of the antigen.  The unlabelled (or "cold") antigen from 
the plasma will compete with the radiolabelled (or "hot") antigen in binding the 
antibody. The more plasma added, the more the “cold” antigen will replace the “hot” 
antigen. The ratio of antibody-bound radiolabelled antigen to free radiolabelled antigen 
will thus decrease. Antibody-bound antigen can then be removed from the solution and 
the remaining free radiolabelled antigen measured with a gamma counter. The process 
is illustrated in next page’s figure.  
 
In order to calculate the exact amount of antigen in patient plasma, the experiment is 
repeated with known standards. Amounts can then be derived from a comparing 
binding curve. Cross-reactivity with other antigens, the sensitivity of the assay (the 
limit of detection) and the intra-assay coefficient of variation are factors to consider. 
The latter describes the degree to which results differ between duplicates (the variation 
within the same data set).  
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Other immunoassays  
Since the development of the RIA, many advances in automation and sensitivity of 
immunoassays have been made. Technologies frequently used today include the 
Fluorescence Polarization Immunoassay and Microparticle Enzyme Immunoassay. The 
Microparticle assay is suitable for larger molecules (e.g. cancer markers or thyroid 
hormones), whereas the Fluorescence assay is utilised for measurement of smaller 
toxicology substances such as therapeutic drugs.  
 
In study III we used a fluorescence polarisation immunoassay kit to measure serum 
paracetamol concentrations. In these assays antigen is typically bound to a fluorescent 
label and competes with unlabelled antigen from the sample. A measure of the number 
of larger antibody-antigen complexes as opposed to smaller antigen-fluorescein 
molecules can be obtained by means of the ability of slower-moving, larger particles to 
polarise light.  
In studies II and III we used the Abbot IMx insulin assay, a micro-particle enzyme 
immunoassay, to quantify insulin concentrations in serum samples. This competitive 
assay utilises the isolation of antibody/antigen complexes on a solid phase surface of 
small beads called micro-particles. It has high specificity, sensitivity and no cross-
activity with pro-insulin. The clinical relevance of pro-insulin has not yet been 
established.  
 
When discussing enzyme assays, the well-known enzyme linked immunosorbent assay 
(ELISA) should be mentioned. Antibody or antigen is labelled with an enzyme, which 
coats a solid phase material, normally a microtiter plate. The enzyme converts a 
substrate to a product with a resulting signal, e.g. a colour change, which can be 
measured. We used an ELISA to detect HP presence in studies II and III. 
 
Other enzymatic methods 
In studies I, II and III we quantified glucose with the Roche glucose-assay on a 
Modular P instrument. This assay is a glucose specific enzyme assay, which means that 
it measures enzymatic activity. All enzyme assays measure either the consumption of 
the substrate or production of the product over time. The Roche assay is based on the 
reduction of NAD+ by means of a two-step reaction.  
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The product can be spectrophotometrically detected due to an increase in light 
absorbance of the assay solution at 340 nm. If the light in a spectrophotometric assay is 
in the visible region, one can actually see a change in the colour of the assay, so-called 
colorimetric assays. Other methods for measuring product generation during enzymatic 
reactions are based on fluorescence, chemiluminescence or radioactivity. 
 
 
3.4 GASTRIC EMPTYING 
The gastric emptying process can be studied with a range of different methods. 
Scintigraphy is the gold standard; other techniques include aspiration of stomach 
content [53], ultrasonography  
[54], magnetic resonance imaging [55], impedance measurements [56], breath tests [57] 
and absorption tests with pharmacological tracers [58]. We used scintigraphy in studies 
I and II. In study III, we chose the paracetamol absorption test for reasons of 
feasibility - it is easy to use, well tolerated and the tracer (paracetamol) can be 
measured in plasma samples.  
 
Scintigraphy 
In scintigraphy, the radiation emitted by radiolabelled tracers within the body (e.g. after 
intake of a labelled meal) is followed by a Gamma camera. This camera consists of at 
least one detector, which absorbs and counts gamma photons and is connected to a 
computer that converts the information into two-dimensional images. The most 
commonly used tracer is technetium-99m (99mTc), which has a relatively long half-life 
and can be incorporated in a variety of molecules.  
 
In studies I and II the meal consisted of a 310-kcal omelette with 99mTc -labelled 
macro-aggregated albumin. In order to imitate a normal meal situation, a non-labelled 
70-kcal carbohydrate soft drink was imbibed as well. A dual head gamma camera was 
used, which obtained both anterior and posterior acquisitions every 5 min during the 
first 50 min, thereafter every 10 min for 70 min and finally one acquisition at 180 min.        
                      
Geometric mean values of the acquisitions in a linear fit model were used to determine 
the linear emptying rate. The mid gastric band separating the antrum and fundus, 
indicated by an arrow in next page’s figure, could be identified in all cases and 
emptying parameters were studied separately for the antrum and fundus in study II. 
Apart from the emptying rate, the lag phase, defined as the time from meal termination 
until 10% of the radioactivity had left the stomach, was studied, as was half-emptying 
time (T50), defined as the time from meal termination until 50% of the radioactivity had 
left the stomach as well as retention at 120 min (Ret120) defined as the percentage of 
radioactivity remaining at 120 min. 
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Paracetamol emptying test  
Tracer methods for the study of gastric emptying rely on intestinal absorption of a 
tracer marker. Paracetamol is mainly absorbed in the duodenum, and serum 
paracetamol has been shown to correlate with the emptying of liquids [59, 60]. A 
gastric emptying profile can be generated after conversion of serum levels to 
cumulative values, reflecting the total absorption of paracetamol for 180 min after the 
meal.  
In study III, we added commercially available effervescent paracetamol tablets to a 
nutrient drink in the single meal experiment. Paracetamol in serum samples was 
analysed by fluorescence polarization immunoassay technology. Disadvantages with 
paracetamol are varying pharmacokinetics between individuals and that the grinding 
function of the antrum is not tested due to the fact that the test is only applicable with 
liquid intake.  
 
 
3.5 HELICOBACTER PYLORI TESTING 
Various methods have been developed for HP diagnosis, including histological 
examination, culturing, the rapid urease test, urea breath tests, serology, PCR and faecal 
antigen testing. Endoscopic tests are preferable for primary diagnosis in patients 50 
years (depending on the cancer incidence) and older in the clinical setting, while for 
younger patients alternative strategies are available [61, 62].  
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Rapid urease test 
In study III, results from rapid urease testing from endoscopic examination were 
available for nine FD patients. Urease is an enzyme produced by HP and not normally 
found in the human stomach. Urease converts urea to ammonia, resulting in a pH 
change that is detected by the test.  
 
Serology 
All remaining subjects in study III were examined serologically for the presence of HP. 
The commercially available ELISA Pyloriset EIA-G III kit was used to detect both IgG 
and IgA antibodies in serum, see chapter 1.3.3.3 for the ELISA concept. A 
disadvantage with serology is that the antibody concentration drops very slowly after 
eradication therapy and positive subjects might not have had active infection at the time 
of the study.  
 
Microscopic evaluation 
In study IV, one antrum and one fundus biopsy from each subject were stained with 
Giemsa dye, which colours human and bacterial cells purple and pink respectively. 
This allowed HP to be diagnosed in a light microscope. Giemsa is not HP specific and 
HP morphology has to be evaluated in order to increase specificity. As HP “likes to 
hide” beneath the mucus layer and in the crypts, the stain must be examined with 
relatively high power in order to definitively identify the organism. PPI or eradication 
treatment can lead to inhibition of urease activity and redistribution of the organism to 
the fundus. For this reason we examined biopsies from both antrum and fundus and the 
participants were considered positive if bacteria were present in either.  
 
 
Helicobacter+pylori+hiding+in+a+gastric+pit,++
Giemsa+stained.+Courtesy+of+Steen+Seier+Poulsen.++
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3.6 PSYCHOMETRIC MEASUREMENTS 
Dyspeptic symptoms cannot be directly measured. Different rating scales have been 
applied for quantification and statistical analysis of subjective measures. The visual 
analogue scale (VAS) is a continuous line between two endpoints (usually 100 mm in 
length) on which the human research subject marks his/her level of agreement. The 
score is determined by measuring the distance to the mark in millimetres. In contrast to 
discrete scales, continuous (analogue) scales capture the idea that symptoms are a type 
of continuous or ordinal data. As the assessments are clearly subjective, the scales are 
probably most valuable in situations when following a change within the same 
individual. In order to avoid overestimating a VAS when comparing groups, one can 
instead use methods based on the ranking of scores rather than their exact values. Our 
questionnaires included a number of ranking scores where the respondent rates his/her 
agreement on a verbal rating scale, which consists of a series of descriptive words (e.g. 
no pain, mild pain, moderate pain, severe pain).  
 
 
3.7 STUDY POPULATIONS 
Characterisation of patients 
Patient material was included in studies III, IV and V. At the time of the data analysis 
the golden rule was characterisation of FD patients according to the Rome III criteria, 
which were applied in studies III and IV for patient selection. The material employed 
in study V was from the Kalixanda study [63], which was designed shortly before the 
Rome II criteria were published. In that study, the abdominal symptom questionnaire 
(ASQ) was used to characterise patients and adjusted to fit the Rome II criteria. It was 
possible to sub-classify patients from study V into PDS and EPS (despite the fact that 
these diagnoses are not described in Rome II) as the dominating symptoms were 
obvious. Further inclusion criteria were aged 17-70 years, normal BMI, absence of 
over-consumption of alcohol and no regular medication use including PPI.  
 
Both the Rome II and III criteria require endoscopic evaluation in order to exclude 
structural disease. We therefore recruited subjects for studies III and IV from patients 
referred for an endoscopy by their GP or a physician at the hospital and in whom a 
diagnosis of FD was most likely (patient records were available in most cases and used 
to select potential candidates). It should be noted that referral for an endoscopy is 
usually preceded by a certain severity in symptoms. In contrast, the subjects in study V 
(the Kalixanda study) were sampled from the entire population of two neighbouring 
communities, Kalix and Haparanda, in Northern Sweden, a total of 21,610 inhabitants 
aged from 18-80 years. The age, gender and disease distribution of this population is 
representative of the Swedish national average [63]. A sample of 1,001 adults (1,000 
with biopsies) aged between 20 and 80 years were invited for upper GI endoscopy.  
 
In studies III and IV, the gastrointestinal symptom rating scale (GSRS), which is a 
validated instrument comprising 15 items for the assessment of GI symptoms in IBS 
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and peptic ulcer disease was used to exclude co-morbidity (Appendix). Furthermore, 
non-validated Swedish and Danish versions of the dyspepsia questionnaire developed 
by Jan Tack and colleagues [36, 64] were used to confirm diagnosis and sub-classify 
patients into PDS and EPS respectively (Appendix).  
 
In study V, the ASQ was used. It has been validated in Swedish as well as Finnish and 
found to be reliable and reproducible [63, 65]. Questions focused on the presence or 
absence of abdominal symptoms from the lower and upper gut as well as on dyspeptic 
symptoms over the preceding 3 months (Appendix).  
All questionnaires were self-administered.  
 
Recruitment of healthy subjects 
Healthy volunteers recruited by advertisement participated in studies I, II, III and IV. 
They had to be free of previous or present diseases, not on any form of medication and 
have no dyspeptic symptoms. In order to detect significant differences and based on our 
experience from previous studies, we aimed to include nine healthy subjects in 
crossover experiments (studies I and II), twenty healthy controls in study III and ten 
healthy controls in study IV, with a 1:2 ratio between healthy subjects and FD patients 
in the latter two studies. Healthy controls in studies III and IV were asked to answer 
the same questionnaires as the patients and absence of symptoms could generally be 
confirmed.  
 
Endoscopic sampling 
Endoscopic biopsies were examined in studies IV and V. In study IV, biopsies were 
obtained from the duodenum at the border between the duodenal bulb (D1) and the 
descending duodenum (D2) using standard biopsy forceps. In study V, biopsies were 
obtained from both D1 and D2. Endoscopists were unaware of the subjects’ symptoms 
before and during endoscopy.  
 
 
3.8 STATISTICAL EVALUATION 
Data description 
We investigated complex and multi-factorial pathophysiological mechanisms in a 
heterogeneous disease, which required the use of miscellaneous experimental 
approaches and resulted in both categorical and numerical data, the latter mainly 
continuous. Whenever possible, we calculated mean ± standard error of the mean 
(SEM) to sum up the individual measurements. In study III, we completed data 
description with area under the curve (AUC) for both serum concentrations and VAS 
measurements, to include the factor of time and get an impression of the total process. 
In MUAS chamber experiments in study IV, increasing doses of 5-HT as stimulator 
were used and we calculated dose-response relationships in order to consolidate 
causality and thus reliability of the measurements. More specifically, the relationship 
between the concentration of 5-HT and induced SCC was investigated using a linear 
model, with treatment and log-transformed concentration as fixed effects.  
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Validation of results 
As stated above, the aim of statistical analysis is to use the newly gained information to 
make inferences about a population of interest (e.g. FD patients). We approached the 
matter statistically by starting out with a number of hypothesises about FD disease, 
designing studies to test those, and using P-values to indicate the strength of findings. 
P-values create an artificial dichotomy between significant and non-significant results, 
which is a simple and descriptive way of validation. Since our measurements were 
generally normally distributed, and observed differences could occur in two directions 
(e.g. patients might show both increased or decreased gastric motility compared to 
controls), the choice of statistical cut-off was a two-tailed P-value < 0.05.  
 
One should keep in mind that a statistical significant difference does not mean the 
result is clinically significant, but must be further evaluated based on the purpose of the 
study and clinical experience. The fact that we used small sample sizes increases the 
risk of type II errors. Our results should be regarded hypothesis generating and 
substantiating, but not proving.  
 
Study I and II were small, randomized controlled trials with a single-blinded cross-
over design on separate days, and at least one week apart to ensure wash-out of 
administered substances. There are several advantages to a cross-over design. Each 
subject serves as his/her own control, which minimizes confounding factors. The 
design is statistical efficient and requires fewer subjects than non-cross-over designs or 
other repeated measures designs.  
 
Study III-V were case-control studies, in which data from FD patients was compared 
to data from healthy controls. The choice of an appropriate control population is 
fundamental for correct interpretation of the results. In study III and IV healthy 
controls were recruited during the same time period and in the same area as the 
patients. Patients were randomly selected from incoming upper endoscopy referrals 
during a certain time period at Karolinska and Bispebjerg hospital respectively. The 
question of whether or not one has a representative sample is a typical problem in 
statistical evaluation. We characterized our patients well, which partly eliminates this 
problem. Furthermore, in study V data from a population study was used, including 
even non-health care seeking individuals. The design of study V is best described as a 
nested case-control study, since we only used selected portions of the material in our 
experiments. 
 
Data comparison 
In study I and II, experiments were repeated in the same individuals, so data was 
compared as paired observations. Changes in appetite scores were calculated as the 
difference before and three hours after meal intake, and compared between two groups 
(saline versus Ex(9-39); study II) using the Wilcoxon rank-sum test and between three 
groups (PYY1-36 versus PYY3-36 and saline; study I) using the Friedman's test 
followed by Dunn's test (study I).  
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Evaluation of the emptying curve and plasma patterns of hormones was performed with 
repeated measures analysis of variance (ANOVA) followed by the Bonferroni test 
(study I and II). The ANOVA tests whether or not the means of several groups are 
equal and can be looked upon as a t-test that has been generalized to more than two 
groups. The Dunn’s and Bonferroni are so called post-hoc tests, which have been 
developed to point out the groups between which detected differences are significant.  
 
We had no paired samples in the remaining studies, and therefore used the commonly 
applied unpaired t-tests to compare mean values of two groups in the majority of cases: 
• AUC values between patients and controls (study III) 
• Basal VAS scores between patients and controls (study III) 
• Basal SCC and conductance between patients and controls (study IV) 
• Stimulated SCC before and after application of glucose or 5-HT to the MUAS 
chamber (study IV) 
• Numbers of stained cells between patients and controls (study IV and V) 
 
To compare mRNA levels between patients and controls we chose instead to use the 
Wilcoxon rank-sum test (in the manuscript referred to as the Mann-Whitney U-test). 
 
For analysis of three independent groups one-way ANOVA followed by the Bonferroni 
test was applied, as indicated in comparison of EPS and PDS versus controls with 
regard to hormone levels (study III) and number of stained cells (study V). 
 
In study III we also aimed at determining the degree of correlation between different 
symptoms and basal values as well as AUC of serum GLP-1, and applied the Pearson’s 
correlation method in that purpose. This method reflects the degree of linear 
relationship between to independent variables. The resulting figure ranges from +1 to -
1 and a correlation of +1 means that there is a perfect positive linear relationship. 
 
We used Prism 5.0 for Windows and SAS version 8.2 for all statistical analysis. 
 
 
3.9 ETHICAL CONSIDERATIONS 
All studies in this thesis were performed in accordance with the Declaration of 
Helsinki. Ethical approval was obtained from the regional ethics committees in 
Stockholm (Studies I, II, III and IV), Copenhagen (Study IV) and Umeå (Study V) 
as well as the radiation protection committee of the Karolinska University Hospital 
(Study I and II). Plasma was stored in a registered bank for biological samples and 
destroyed after analysis. All subjects provided written informed consent prior to 
participation. Endoscopy and insertion of an intravenous catheter led to a certain degree 
of discomfort for the subject. Many FD patients experienced their usual symptoms after 
food intake. We designed our studies in a way that ensured interpretability of the results 
and considered that their significance for clinical practice and future research 
outweighed the minor discomfort for the patients involved.  
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4 RESULTS 
4.1 ROLE OF GLP-1 AND PYY IN GASTRIC MOTILITY 
In study I, eight healthy volunteers participated and emptying patterns were studied as 
the subjects received an intravenous saline infusion, PYY1-36 or PYY3-36, on separate 
occasions. Both PYY1-36 and PYY3-36 affected gastric emptying. PYY3-36 slowed 
the emptying rate (from 0.99 ± 0.09 to 0.60 ± 0.05% min-1) and prolonged the T50 (from 
63.1 ± 5.2 to 87.0 ± 11.5 min), whereas the lag phase was unaffected, Figure 1. PYY1-
36 did not have any significant effect on the gastric emptying rate, T50 or lag phase, but 
both PYY1-36 and PYY3-36 had higher Ret120.  
 
 
 
 
Figure 1 Mean ± SEM plasma concentrations of peptide YY (PYY) during IV infusion of saline (●), 0.8 
pmolkg-1min-1 PYY1-36 (■) or PYY3-36 (□) in eight healthy human volunteers. The infusion began at 
10 minutes (-10) before meal intake and continued for 190 min. ⁎ indicates time points with significant 
differences between saline and PYY1-36 and # between saline and PYY3-36. 
 
 
In study II, nine healthy adults participated in two separate emptying tests during 
infusion of either saline or Ex(9-39). The latter did not affect the total gastric emptying 
curve, lag phase, T50 or Ret120. Differences were, however, observed with regard to 
intra-gastric distribution. During Ex(9-39) infusion, significantly more content 
remained in the fundus (at 5 min (79.1 ± 2.5% of total ingested amount) compared to 
during saline infusion (66.6 ± 5.7%). Antrum motility was concurrently affected with a 
slower increase in intra-antrum content during Ex(9-39) infusion. 
 
In study III we investigated the gastric emptying rate in 36 FD patients and 18 healthy 
controls and found no significant difference between the groups. Patients completed the 
dyspepsia questionnaire and underwent gastroscopy before examination in order to rule 
out pathology in the oesophagus, stomach and proximal duodenum.  
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4.2 EFFECT OF GLP-1 AND PYY ON ENDOCRINE PANCREATIC 
FUNCTIONS AND GLUCOSE CONTROL 
Insulin secretion 
In study I, insulin levels increased from pre-meal levels of 75.7 ± 9.7 to a maximum of 
170.5 ± 8.1 pmolL-1 30 min after food intake. Compared to saline, both PYY1-36 and 
PYY3-36 significantly moderated the postprandial rise in insulin. Despite the fact that 
the AUC for the whole period was not affected, the AUC30–60 for insulin was 
decreased by PYY3-36, but not by PYY1-36 (AUC30–60 9.3 ± 4.9 nmolmin-1 for 
saline, 7.4 ± 3.8 for PYY1-36 and 6.8 ± 3.4 for PYY3-36). 
 
In study II, Ex(9-39) did not affect preprandial insulin levels, but the postprandial rise 
in insulin was significantly enhanced, Figure 2.  
 
 
Figure 2 Plasma levels of glucose, insulin and 
glucagon. Plasma concentrations of glucose, 
insulin and glucagon during IV infusion of saline 
(☐) or 300 pmolkg-1 min-1 Ex(9-39)amide (●) in 
nine healthy human volunteers. “Meal” indicates 
the time it took to consume a 310-kcal solid meal. 
Mean ± SEM * indicates significant differences 
with P < 0.05. 
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In study III, we found a difference in insulin secretion between FD patients and 
healthy controls after the single meal. The AUC for insulin was significantly higher in 
FD patients (P = 0.030). When patient groups were divided into EPS and PDS, the 
difference in the AUC for insulin remained significant for EPS (P = 0.047).  There was 
no such difference during the satiety test (P = 0.22).  
 
Glucose control 
In study I, glucose increased as expected during saline infusion from pre-meal levels of 
5.1 ± 0.2 to a maximum of 6.1 ± 0.4 mmolL-1 after food intake. Neither PYY1-36 nor 
PYY3-36 had any significant effects on that rise or on the glucose level AUC.  
 
In study II, preprandial glucose levels were not affected by Ex(9-39), but the 
postprandial rise was significantly enhanced, Figure 2. We found that during Ex(9-39) 
infusion, plasma glucagon levels were markedly increased at all times, including before 
the meal (after 40 min of Ex(9-39) infusion the glucagon level was 15.1 ± 0.7 
compared to 5.4 ± 1.4 pmolL-1 during saline infusion.  
 
In study III, FD patients and healthy controls had similar postprandial glucose patterns.  
 
Changes in GLP-1 concentrations 
In study I, the GLP-1 basal level was 14.0 ± 1.6 pmolL-1 and neither the meal nor the 
infusion of the two forms of PYY had any significant effect on it. 
 
In study II, basal and postprandial GLP-1 levels during saline infusion were similar to 
those measured in study I. During Ex(9-39) infusion however, a statistically significant 
rise in postprandial GLP-1 concentrations was observed.  
 
In study III, basal levels of GLP-1 were similar to those reported in studies I and II. 
In contrast to previous studies, there was a clear postprandial rise, both after the single 
meal and during continuous food intake. There was no difference in the AUC of GLP-1 
levels between FD patients and healthy controls.  
 
 
 
4.3 DYSPEPTIC SYMPTOMS AND SATIETY MEASURES – ROLE OF 
GLP-1 AND PYY 
Nausea 
In study I, three of the first four subjects spontaneously reported nausea on one of the 
study occasions, which was subsequently identified as that of the PYY3-36 infusion. In 
the following subjects, nausea was rated using a 100 mm VAS 10 min before the meal, 
as well as 10, 30, 60, 120 and 180 min after it. Nausea was documented in the same 
way in studies II and III.  
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Compared to VAS ratings 10 min before the infusion, VAS for nausea increased 
significantly during PYY3-36 infusion in the healthy subjects (maximum at 120 min 
with VAS score of 50.3 ± 15.9 mm). Neither PYY1-36 nor Ex(9-39) infusions induced 
nausea in any subject, Figure 3.  
 
 
 
 
Figure 3 VAS rating for nausea after intake of a solid meal during IV infusion of saline (●), 0.8 pmolkg-
1 min-1 PYY1-36 (■) or PYY3-36 (□) in four healthy human volunteers; P < 0.05 for PYY3-36 vs. saline. 
 
 
Compared to healthy controls, FD patients experienced nausea to a significantly higher 
degree after meal intake (Study III, P < 0.0001) as well as before meal intake (P = 
0.0025, time -10 min) and during the satiety test (continuous food intake, P = 0.027, 
AUC). Correlations between GLP-1 and symptoms were studied for basal levels (10 
minutes before meal intake) and for the AUC.  The AUC of GLP-1 correlated with that 
of nausea in both groups after the single meal (P = 0.015 for controls and 0.041 for 
FD), but not when analysed for continuous meal intake (satiety test). 
 
Hunger, desire to eat, prospective consumption and satiety 
In studies I, II and III, hunger, satiety, desire to eat and prospective consumption were 
rated in the same way as nausea (see above).  
 
Neither PYY1-36 nor PYY3-36 had significant effects on the desire to eat, hunger and 
satiety ratings. The prospective consumption rating decreased significantly on infusion 
of PYY3-36 but not PYY1-36, Figure 4 (the change in VAS score between -10 and 180 
min was 9.5 ± 13.2 mm for PYY1-36, 39.5±7.7 mm for PYY3-36 and 4.1±12.5 for 
saline).  Compared to saline, Ex(9-39) infusion did not affect ratings in any way. FD 
patients reported significantly higher prospective consumption scores after single meal 
intake in study III (P < 0.0001 for differences in the AUC). Ten minutes before meal 
intake, patients had a significantly higher level of satiety (P = 0.028). There was no 
significant correlation between GLP-1 levels and appetite ratings in study III, except 
for the AUC GLP-1 versus desire to eat for FD patients in the satiety test.  
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Figure 4 VAS rating 100 mm (actual values) for desire to eat, hunger, satiety and prospective 
consumption, performed after intake of a solid meal during IV infusion of saline (●), 0.8 pmolkg-1min-1 
PYY1-36 (■) or PYY3-36 (□) in eight healthy human volunteers. 
 
 
In study III, subjects also underwent the satiety drinking test. FD patients reported 
satiety after a mean time of 41 minutes (range 13-102), which corresponds to a 917 kcal 
intake. Healthy controls felt sated at 51 minutes (range 27-93, calorie intake 1,158 
kcal), which was not significantly different from FD patients.   
 
Sensation of fullness, bloating and pain 
In study III, fullness, bloating and pain were also rated. Major differences were 
observed regarding the AUC after single meal intake, with significantly higher scores 
in patients (P = 0.0097 for differences in AUC fullness, P = 0.011 for AUC bloating, P 
= 0.0072 for AUC pain). Ten minutes before meal intake, patients had a significantly 
higher level of fullness (p = 0.019) and pain (P = 0.042), but not bloating. During the 
satiety drinking test, patients had significantly higher scores for bloating (P = 0.010) 
and pain (P = 0.015), but not fullness. 
 
Correlations between GLP-1 and symptoms were studied for basal values (at -10 min) 
and the AUC, Table 1. There was a significant correlation between baseline GLP-1 
values and the sensation of fullness before the single meal in the control group (P = 
0.0096). In controls, the AUC of GLP-1 correlated with that of pain (P = 0.015). 
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4.4 SEROTONIN AND EPITHELIAL FUNCTION IN FUNCTIONAL 
DYSPEPSIA 
Immunohistochemistry 
In study IV, we invited healthy volunteers and patients with dyspeptic symptoms 
referred for gastroscopy at Bispebjerg Hospital (Copenhagen, Denmark) who fulfilled 
the ROME III criteria to participate. The dyspepsia questionnaire and GSRS were used 
to characterize subjects and differentiate “pure” FD from co-morbidity with IBS and 
reflux disease. Duodenal biopsies from 15 FD patients and 18 healthy controls were 
included in the histological studies. Gastric biopsies from the same subjects were 
assessed histologically for the presence of HP and one of the FD patients was found to 
be positive. 
 
Biopsies varied with regard to depth. All contained an intact surface epithelium and 
lamina propria. Several included the lamina muscularis mucosa, while others contained 
part of the sub-mucosal layer with Brunner’s glands. Epithelial damage ranged from 0-
3 in both groups (mean score 0.7 in FD and 1.1 in healthy controls) with no significant 
difference (P = 0.179). The cell architecture was normal in both FD patients and 
healthy controls.  
 
5-HT stained cells were found in the epithelium and Brunner’s glands, Figure 5. Only 
the epithelium was examined, as not all biopsies contained sub-mucosal tissue. The 
mean number of cells per HPF was 34.4 ± 8.4 in FD patients and 30.4 ± 3.70 in healthy 
controls with no significant difference between the groups (P = 0.647). 
 
 
 
Figure 5 Paraformaldehyde-fixed duodenal tissue from a patient with functional dyspepsia. The tissue 
was immunohistochemically stained using a polyclonal antibody against serotonin (5-HT). There are 
many 5-HT immunoreactive cells in the surface epithelium, both in the crypts and in the villi. The biopsy 
has an intact surface epithelium with no signs of mechanical damage (magnification ×220). 
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In study V, we examined slides from the Kalixanda study, in which a random sample 
of an adult Swedish population (n = 1001) completed the ASQ and underwent upper 
endoscopy. Biopsies from several sections were taken including D1 and D2.  We had 
access to a randomly selected portion of the material and identified the following 
groups: 24 FD patients and 12 healthy controls from D1 as well as 16 FD patients and 
15 controls from D2.  
 
FD patients and healthy controls exhibited normal architecture in the D1 and D2 
regions. Slides were examined to establish the number of CGA and 5-HT stained cells, 
and the same HPF were evaluated for both substances. The number of cells was then 
expressed as cells per mm2. Single stained cells were found in the epithelium, more 
specifically in the Lieberkühn crypts. There was no significant difference in the number 
of 5-HT stained cells (D1 P = 0.77, D2 P = 0.70). The number of CGA positive cells 
was significantly lower in FD patients both in D1 (P = 0.010) and D2 (P = 0.038), 
Figure 6. 
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Figure 6 The number of Chromogranin A (CGA) and serotonin (5-HT) positive cells in the duodenal 
bulb and second part of the duodenum per mm2, respectively. Comparison between FD and controls. 
 
 
Based on the Rome III criteria and results from the ASQ, patients were further divided 
into EPS and PDS. The number of CGA but not 5-HT stained cells was found to be 
significantly decreased in D1 in EPS (CGA P = 0.028, 5-HT P = 0.94). There was no 
such difference in D2 (CGA P = 0.083, 5-HT P = 0.54).  
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Ussing chamber experiments 
In study IV, duodenal biopsies from 15 FD patients and 18 healthy controls were 
mounted in MUAS chambers. Mean basal SCC was 19.8 ± 3.0 µAcm-2 for the FD 
patients and 21.4 ± 3.7 µAcm-2 for the healthy controls with no significant difference 
between groups (P = 0.749). The addition of cumulative concentrations of 5-HT in 
steps of a factor of three from 3 to 243 µmol•L-1 on the serosal side induced a dose 
dependent SCC rise in both FD patients and healthy controls, Figure 7. The 5-HT-
induced rise in SCC was significantly lower in FD patients (P < 0.001 for the overall 
difference). Glucose control values after 5-HT stimulation yielded a mean magnitude of 
12.5 ± 2.0 µAcm-2 for FD patients and 12.1 ± 2.5 µAcm-2 for healthy controls (P = 
0.906). 
 
 
 
 
Figure 7 Dose-response curve of serotonin (5-HT)-induced short-circuit current (SCC). Addition of 
cumulative concentrations of 5-HT in steps of a factor of three from 3 to 243 µmol/L on the serosal side 
of duodenal biopsies mounted in a MUAS chamber resulted in an increased SCC (µA/cm2) in both FD 
patients (■; n = 8) and healthy controls (●; n = 9), with significantly lower values in the FD group (mean 
± SE).  
 
Basal conductance, in millisiemens per square cm (mScm-2), was significantly lower 
in FD patients compared to healthy controls (42.4 ± 4.7 mScm-2 and 62.4 ± 4.5 
mScm-2 respectively, P = 0.005). Histological examination revealed that the surface 
epithelium and entire lamina propria were intact in all samples after mounting and the 
experimental period. 
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Polymerase chain reaction 
In study IV, gene expression levels for 5-HT receptors 1A, 1B, 2A, 2B, 3A, 3B, 3C, 
3D, 3E, 4 and 7 were quantified. Expression levels were undetectable for three receptor 
genes, HTR1A, HTR3B and HTR3D. Expression of HTR1B, HTR2A, HTR2B, 
HTR3A and HTR3C was very low. However, the receptor genes HTR3E, HTR4 and 
HTR7 were strongly expressed. Expression of HTR3E was significantly higher (P = 
0.008) and HTR7 significantly lower in FD patients (P = 0.027) compared to healthy 
controls. There was no significant difference in expression of HTR4 between the two 
groups.  
 
SLC6A4 and the TPH1 gene were also quantified and found to be strongly expressed in 
all duodenal biopsies. There was a significant difference in expression level between 
FD patients and healthy controls, with FD patients exhibiting higher expression of 
SLC64 (P = 0.033) and lower expression of the TPH1 gene (P = 0.031). The number of 
biopsies studied for each gene was 8-10 for FD patients and 13-16 for healthy controls.  
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5 DISCUSSION 
5.1 THE ROLE OF GLP-1 AND PYY IN GASTRIC MOTILITY 
In animal studies, both PYY isoforms have been found to slow down the gastric 
emptying rate and T50, with PYY3-36 being ten times more effective in rats. In healthy 
humans, our results confirmed an inhibiting role of PYY3-36 in all gastric emptying-
related parameters. PYY1-36 increased Ret120, but did not significantly change the 
other parameters. This is probably due to lack of power. While a sample of nine 
subjects is large enough to detect differences, type II errors (false negative outcomes) 
can still occur. A larger meal or higher dose of PYY1-36 could have led to increased 
power. The fact that PYY3-36 seems to be more effective might be a consequence of 
the different receptor binding profiles. The Y1 receptor mediated action in vagal parts 
of the brainstem in rats, leading to increased gastric motility, while the Y2 receptor 
mediated inhibition of motility [66].  PYY3-36, which is Y2 receptor specific, might 
thus exert its motility inhibiting action centrally through vagal efferent mechanisms, but 
this aspect remains to be elucidated. PYY1-36 has similar affinity to the Y2 receptor as 
PYY3-36 but in the physiological situation this form is not as prevalent in plasma. In 
addition, PYY1-36 targets other PYY receptors, and a motility inhibiting effect via Y2 
receptors might be counteracted by activation of the Y1 receptor [67].   
We could not confirm that endogenous GLP-1 plays a role in the gastric emptying 
process, but instead observed differences in the motility pattern in various gastric 
regions, suggesting that endogenous GLP-1 has an alternative regulating role in the 
intra-gastric distribution of food. When the action of endogenous GLP-1 is inhibited 
during Ex(9-39) infusion, food remains in the fundus for a longer time before being 
transported to the antrum. Based on this finding, one would expect blood GLP-1 levels 
to result in a more rapid transport of food to the antrum and consequently an increased 
emptying rate. However, in previous studies both exogenous and endogenous GLP-1 
have been observed to inhibit the overall emptying rate [68-71], and the question is 
whether our results might represent a type I error.  The calorie content of our meal was 
smaller and the food composition differed from similar studies. A larger meal could 
result in increased endogenous GLP-1 secretion, even during Ex(9-39) infusion.  
 
In our study, circulating GLP-1 concentrations were actually higher during Ex(9-39) 
infusion than during saline infusion. This means that even if the GLP-1 receptor is 
inhibited, the GLP-1 hormone could potentially mediate the effects of other 
mechanisms, as well as counteracting those induced by Ex(9-39). Higher GLP-1 
concentrations during Ex(9-39) infusion might be explained by autocrine feedback.  
 
Schirra et al. published a study performed in healthy humans, where nutrients were 
infused into the duodenum with and without simultaneous intravenous Ex(9-39) 
infusion [72]. Gastric motility was assessed by means of barostat and manometry (a 
technique for measuring intraluminal pressure). Duodenal nutrients stimulated 
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relaxation of the upper stomach as well as inhibition of antrum activity. Antrum 
motility returned during Ex(9-39) inhibition, which supports the assumption that 
antrum inhibition is mediated by GLP-1. Inhibition of antrum activity has recently been 
observed after intra-duodenal infusion of protein [73], which also resulted in increased 
circulating GLP-1 levels. If the smooth muscles in the antrum wall contract during 
Ex(9-39) infusion, antral reception of food is hampered, which can explain why a meal 
remains in the upper part of the stomach for a longer period. 
 
In the context of gastric motility, it should be taken into account that liquid meal 
components were used in all our emptying studies. Theoretically, acceleration of liquid 
emptying during Ex(9-39) infusion could lead to redistribution of the solid meal 
components towards the upper stomach.  Liquid components reaching the small bowel 
would also result in higher glucose and insulin levels. Hyperinsulinemia has been 
shown to delay gastric emptying independently of glucose [74]. Post-prandial levels 
were higher during Ex(9-39) infusion in our study, which could have had an inhibitory 
effect on gastric emptying that outweighed the potentially accelerating effect of Ex(9-
39). We also found high glucagon levels during Ex(9-39) infusion, glucagon being 
another known inhibitor of the gastric emptying rate. The relative importance of liquid 
components should be further investigated in future experiments using dual-label 
scintigraphy. In general, liquid meals do not trigger gastric motility to the same extent 
as solid ones, which might explain why we did not observe any difference in gastric 
emptying patterns between healthy controls and FD patients in study III, in which intra-
gastric motility changes were not assessed. 
Both PYY3-36 and GLP-1 can induce nausea, which has been hypothesized to result 
from reduced gastric emptying. One could also hypothesize that nausea per se causes 
inhibition of gastric motility.  
 
 
5.2 EFFECT OF GLP-1 AND PYY ON ENDOCRINE PANCREATIC 
FUNCTIONS AND GLUCOSE CONTROL 
PYY did not affect glucose levels in our study, but we observed a small inhibition in 
post-prandial insulin secretion, with both isoforms. This is in line with a previous 
human study by Sloth et al., who reported a higher post-prandial insulin response in the 
presence of PYY1-36 and PYY3-36 [75]. These researchers observed increased post-
prandial glucose levels in the case of PYY3-36, which we were unable to confirm. In 
conclusion, there is no strong evidence that PYY has a role in the short-term control of 
glucose homeostasis. PYY3-36 might be linked to the development of insulin 
resistance. High levels of PYY3-36 during fasting have recently been found to be 
associated with insulin resistance independent of body mass  
[76]. 
 
Exogenous GLP-1 is known to stimulate insulin and inhibit glucagon secretion. 
Analogues are used in clinical practice for the treatment of diabetes. In contrast to 
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traditional treatment options, GLP-1 analogues have a lower risk of hypoglycaemia. 
The physiology behind GLP-1 related glucose homeostasis is not yet fully investigated.  
 
The GLP-1 inhibitor Ex(9-39) has been found to suppress the postprandial rise in 
insulin concentrations during application of a hyperglycaemic clamp [77, 78]. The 
clamp provides an opportunity to separate hormone-induced changes from those 
initiated by gastric emptying. The effect of endogenous GLP-1 on postprandial insulin 
levels is believed to be independent of gastric emptying [77], which is in line with our 
findings. Despite the fact that we did not detect any effect on the gastric emptying rate, 
endogenous GLP-1 leads to enhanced post-prandial insulin levels. We also found 
higher glucose levels, thus it could be assumed that the insulin increase is a 
consequence of greater glucose concentrations. Likewise, studies by Deane et al. and 
Edwards et al. identified increased glucose and insulin levels during Ex(9-39) infusion 
after meal intake [68, 79].  
 
In contrast to changes in glucose and insulin concentrations, which only occurred after 
luminal food stimulation, we found glucagon levels to be constantly suppressed by 
Ex(9-39), even during fasting. Our finding that endogenous GLP-1 concentrations are 
sufficient to inhibit glucagon secretion in a consistent manner is in line with previous 
results [80]. Glucagon is known to be strongly involved in short-term control of glucose 
homeostasis and prevention of hyperglycaemia. Post-prandial glucose levels should 
naturally be higher during constant glucagon suppression. As pointed out already, the 
effect is meal dependent; glucagon suppression does not affect fasting levels of glucose 
or insulin. 
 
 
5.3 DYSPEPTIC SYMPTOMS AND SATIETY MEASURES – THE ROLE OF 
GLP-1 AND PYY 
Satiety measures 
PYY1-36 did not have any effect on ratings for the desire to eat, hunger and satiety, 
which is in line with earlier studies. There is thus little evidence to suggest that PYY1-
36 plays a role in satiety mechanisms.  
 
The only satiety measure affected by PYY3-36 in our study was prospective 
consumption. A recent study by Sloth et al. [75] using the same infusion doses, 
reported decreased ratings of perceived ability to eat during PYY3-36 infusion. Degen  
. found a reduced hunger score before meal intake [3], but not during or directly after 
the meal. Batterham et al. reported decreased hunger scores and food intake after a two 
hour infusion before meal intake [2]. PYY3-36 definitely seems to be involved in 
regulating food intake, but a longer infusion period before a meal is necessary to detect 
significant effects on hunger scores.  
 
Exogenous GLP-1 has been observed to increase satiety and decrease food intake in 
humans [81]. We did not find evidence of such a role for endogenous GLP-1 in our 
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study. Owing to the relatively small number of subjects, a minor effect on satiety 
parameters may have been overlooked. One could also hypothesize that the satiety 
increasing effect of exogenous GLP-1 is associated with inhibition of gastric emptying, 
as we did not observe a difference in the total gastric emptying rate caused by 
endogenous GLP-1. Further studies are needed to elucidate whether or not endogenous 
GLP-1 is involved in the complex physiology of satiety.  
 
Nausea 
In line with earlier studies [3, 75], we observed that PYY3-36 is capable of inducing 
nausea, which does not, however, seem to be food-related. Sloth et al. and Degen et al. 
used the same dose as in our study, but without a concomitant meal and found that a 
significant proportion of their subjects had to discontinue the PYY3-36 infusion 
because of side effects.  
 
Exogenous GLP-1 frequently causes nausea and vomiting [82, 83]. In study III, we 
measured GLP-1 levels pre- and post-prandially in FD patients, of whom a substantial 
number suffered from frequent nausea, and compared the results with those of healthy 
controls. As expected, the FD patients had significantly higher nausea ratings after meal 
intake compared to controls, although the AUC of GLP-1 concentrations was similar in 
both groups after the meal. In the correlation study, the AUC of GLP-1 correlated with 
that of nausea in both groups. In conclusion, GLP-1 should be regarded a candidate 
mediator in the pathogenesis of nausea, although its role in the pathogenesis of FD is 
unclear.  
 
Other dyspeptic symptoms 
In study III, FD patients presented with high levels of dyspeptic symptoms even at 
baseline. It is not possible to conclude whether these symptoms were present just before 
the meal (and might be induced by expectance of the meal and meal-related symptoms) 
or whether they were unrelated to food intake. In controls, there was a significant 
correlation between baseline GLP-1 values and the sensation of fullness before the 
single meal as well as between the AUC of GLP-1 and that of pain. Such an association 
was not found in patients. The number of subjects was relatively high, which makes a 
type II error unlikely. Patients were also carefully selected and there was no co-
morbidity. Hence, our results do not support an association between altered GLP-1 
secretion and FD symptom development, except in the case of nausea. 
 
 
5.4 SEROTONIN AND EPITHELIAL FUNCTION IN FUNCTIONAL 
DYSPEPSIA 
Our results strongly support a 5-HT receptor mediated pathology in FD. Possible 
mechanisms include impaired HTR3 and HTR7 receptor function in duodenal epithelial 
transport or signalling.  
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Duodenal transport mechanisms were studied in the MUAS chamber, a sensitive 
system easily influenced by external factors. The SCC values in our studies were 
generally lower than those previously described by Engelmann et al. [16], which might 
be explained by the different settings in which the studies were conducted. The 
Engelmann study included different types of dyspeptic patient not covered by the Rome 
III criteria and had no control group, which may also have affected mean SCC 
measurements.  We found lower SCC values in FD patients compared to controls when 
biopsies were stimulated with 5-HT. This can be interpreted as a decreased movement 
of negative ions to the duodenal lumen (which, in the duodenum, are most likely HCO3- 
ions), increased movement of positive ions to the lumen (e.g. potassium secretion), 
decreased hydrogen absorption (from gastric acid) or less absorption of positively 
charged particles (e.g. potassium ions from gastric acid). Since HCO3- secretion is an 
important part of the duodenal defence system, impaired secretion in FD patients is the 
most plausible explanation. One way to further elucidate this aspect would be to repeat 
the study, and include in-chamber pH measurements and/or single dose 5-HT 
stimulation with the subsequent addition of a HCO3- transport inhibitor, e.g. 
acetazolamide, combined inhibition of Cl- secretion by for instance bumethanide 
(which blocks the co-transport of sodium, potassium and Cl- ions). 
 
HTR3 is known to be prevalent in duodenal mucosa [84], which is supported by our 
results. We also found higher expression of the HTR3E sub-type in FD patients 
compared to controls. HTR3E dysfunction in a subgroup of IBS has been suggested 
[85]. As the receptor is a gated cation-selective channel, a specific role in HCO3- 
secretion as part of the altered epithelial transport is plausible, since HCO3- secretion is 
both dependent on transport of sodium and potassium. One possible way of further 
elucidating receptor function in duodenal mucosa is to stimulate biopsies with a single 
dose of 5-HT followed by a specific receptor antagonist. Furthermore, an aspect that 
should be taken into account is the fact that HTR3E does not function alone, as shown 
by patch clamp studies [86] and thus functional studies on HTR3E should include other 
receptor sub-types (at least HTR3C, D, E). However, to date there are no specific 
ligands for the different sub-types. MUAS chamber studies should be performed using 
a general HTR3 antagonist, e.g. ondansetron, which has been in clinical use for many 
years for the treatment of nausea. A recommendation for future studies is to specifically 
target FD patients in whom nausea is the main symptom.  
 
HTR7 is a 5-HT receptor about which very little is known, although it has been 
described as being highly expressed in the stomach and ileum [87]. Receptor activation 
affects intestinal motility in dogs and guinea pigs [88, 89]. We found a high HTR7 
expression in our duodenal samples, but lower expression in FD patients. Future studies 
on the involvement of HTR7 in duodenal epithelial transport would be facilitated by the 
development of a specific ligand, which does not exist at present. 
 
There is also a difference in SERT and TPH1 expression in duodenal mucosa that is not 
associated with the number of 5-HT secreting cells, which we investigated 
immunohistochemically in two independent studies (Studies IV and V). TPH1 
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expression was lower in patients; a similar relationship has been observed in IBS [90]. 
Decreased 5-HT bioavailability might thus be part of the FD mechanism. Gene 
expression of the 5-HT transporter is high in the duodenal biopsies and FD patients had 
increased levels compared to controls. If 5-HT bioavailability is actually decreased in 
patients, higher expression of the transporter protein could be a compensatory 
mechanism.  
 
The total number of endocrine cells is lower in FD. Since the amount of 5-HT is not 
altered, the involvement of other neuroendocrine mediators appears reasonable. 
Although PYY and GLP-1 are possible candidates, the number of cells containing 
GLP-1 and PYY in the duodenal mucosa is low (unpublished results). CGA is also 
found in gastrin and CCK cells. A decrease in CCK producing, but not 5-HT 
producing, cells could explain our results. Co-staining would be a way to further clarify 
this issue.  
 
Differences were specifically found for EPS, which suggests a connection between the 
number of endocrine cells and pain. It has been suggested that EPS and PDS are two 
different diseases. Recent results from Vanheel et al. indicate that epigastric pain seems 
to originate from the duodenal tract and that early satiety is mainly a stomach-related 
symptom [40]. The sample size in study V was rather small, but the patients were well 
characterized and did not suffer from IBS comorbidity. Our results are further 
strengthened by the fact that FD subjects were sampled in a population based manner 
and represented the average citizen rather than a patient seeking healthcare (who 
according to earlier studies suffers from psychological co-morbidity to a higher degree) 
or a patient in need of specialist care (who usually exhibits more severe 
symptomatology).  
 
 
 
Based on the results of this thesis, recommended future studies should include: 
 -­‐ The effects of exogenous GLP-1 on gastric emptying and insulin levels in 
doses that are too low to induce nausea.  -­‐ The number of GLP-1 and PYY expressing cells throughout the intestinal 
tract in EPS and PDS patients.  -­‐ Functional studies of HTR3 receptors in duodenal ion transport in FD 
patients, especially those with nausea as the main symptom. -­‐ mRNA expression of TPH1 and SERT in PDS compared to EPS and controls.  -­‐ Co-staining for CCK, 5-HT and CGA in the duodenal mucosa in EPS, PDS 
and healthy controls.   -­‐ Quantification of mucosal 5-HT staining cells in relation to mast cells, 
eosinophils and intra-epithelial lymphocytes in post-infectious FD compared 
to other FD patients and healthy controls.  
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6 CONCLUSIONS 
Study I  
This work contributes data to support the following conclusions: PYY3-36 and PYY1-
36 both inhibit gastric emptying, PYY3-36 being the most effective. Neither PYY3-36 
nor PYY1-36 influence glucose or GLP-1 concentrations, but both reduce the 
postprandial rise in insulin. PYY3-36 induces nausea in some subjects and reduces 
prospective consumption. The prolonged emptying process might be due to nausea. 
Decreased prospective consumption could be a result of reduced emptying as well as 
nausea. These issues are still to be investigated.  
 
Study II  
Endogenous GLP-1 does not affect the gastric emptying rate but seems to be involved 
in the regulation of gastric motility in relation to food intake and also in the regulation 
of post-prandial insulin and glucose levels. Furthermore, endogenous GLP-1 seems to 
tonically restrain glucagon secretion. Our results support a role of endogenous GLP-1 
as an incretin hormone that is independent of gastric emptying. However, accelerating 
effects of GLP-1 receptor inhibition might have been missed due to enhanced insulin 
and glucagon levels. Both insulin and glucagon have been shown to inhibit gastric 
emptying in previous studies. We did not detect a role of endogenous GLP-1 in 
sensations of hunger, satiety, desire to eat, prospective consumption or nausea. 
 
Study III 
FD patients have higher postprandial insulin levels compared to healthy controls. When 
EPS and PDS are studied separately, increased insulin secretion is found with EPS, but 
not PDS. FD patients have normal postprandial glucose and GLP-1 concentrations. 
Higher satiety, nausea and pain scores in FD patients cannot be explained by delayed or 
accelerated gastric emptying. Nausea might be associated with postprandial GLP-1 
secretion mechanisms.  
 
Study IV  
Duodenal ion transport in response to exogenous 5-HT is abnormal in FD patients, in 
whom exogenous 5-HT also induces higher epithelial electrical resistance. Based on 
previous results it is plausible that the resistance reflects lower HCO3- and Cl- 
conductivity. 5-HT induces a dose dependent rise in SCC in both FD patients and 
healthy controls, but the rise is lower in the former. This can be a result of impaired 
bicarbonate secretion. Genes for the HTR3E, HTR4 and HTR7 5-HT receptors are 
highly expressed in human duodenal mucosa. The SERT gene (responsible for 5-HT 
transport over cell walls) and TPH1 (produces 5-HT in cells) are also strongly 
expressed. FD patients have higher gene expression of HTR3E and SERT and lower 
gene expression of HTR7 and TPH1 in their duodenal mucosal cells. An altered 
amount of HTR3E and SERT might be involved in the mechanisms behind impaired 
duodenal ion transport in response to exogenous 5-HT in FD patients. The number of 
duodenal epithelial cells containing 5-HT is similar in FD patients and healthy controls.  
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Study V  
Adult non-consulting FD subjects have less endocrine cells in the duodenum, as 
indicated by CGA staining, but a normal number of cells containing 5-HT. When EPS 
and PDS are studied separately, the number of endocrine cells is significantly lower in 
the in EPS but not in PDS. As 5-HT expressing cells are not altered, the involvement of 
other neuroendocrine substances, such as PYY and GLP-1, seems likely.  
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7 POPULÄRVETENSKAPLIG SAMMANFATTNING 
”I 10 års tid har jag nu haft jätteont i övre magen, vissa dagar mer än andra. Min egen 
bedömning är magkatarr och jag har självbehandlat med alla receptfria läkemedel och 
dieter som finns, men inget hjälper, det blir bara värre. När jag vänder mig till läkare, 
diagnostiserar de Funktionell Dyspepsi – det betyder att de inte vet vad det är.” 
 
Detta inlägg är taget från ett patientforum på nätet. Författaren till inlägget har rätt. Vi 
vet i dagsläget inte vad Funktionell Dyspepsi (FD) är. FD är ett begrepp som omfattar 
symptom som troligen har sitt ursprung i magsäck och tunntarm men som inte förklaras 
av hittills känd organisk sjukdom, vilket innebär synliga vävnadsförändringar i 
magsäck eller tunntarm, infektion eller metabol sjukdom (exempelvis diabetes). För 
formell diagnos krävs minst sex månaders besvär med smärta eller brännande känsla i 
övre delen av magen, besvärande uppkördhet efter måltid eller tidig mättnadskänsla, 
eventuellt i kombination med andra övre magbesvär, och en normal gastroskopi.  
 
Magens fysiologi är komplicerad och man behöver titta på flera faktorer samtidigt för 
att få en bättre förståelse för uppkomsten av sjukdomar. Vi har undersökt hur olika 
signalämnen som utsöndras i tunntarmens slemhinna påverkar rörelsemönstret i 
magsäcken, sockerbalansen i blodet och upplevelsen av hunger, mättnad, illamående 
och dyspeptiska symtom. Vi har fokuserat på hormonerna (signalämnen som vandrar 
med blodet), PYY1-36, PYY3-36 och GLP-1 och nervsignalämnet serotonin. Vi har 
förutom studier kring magsäckstömning och blodsockerbalans räknat antalet celler som 
utsöndrar dessa ämnen i tolvfingertarmen. Vi har studerat transportmekanismer över 
tunntarmens slemhinna och hur dessa påverkas av signalämnet serotonin. Under 
projektets gång har vi specifikt letat efter och försökt förstå avvikelser hos FD 
patienter, både patienter som sökt vårdcentral och individer som inte känt något behov 
av att söka sjukvård.  
 
När vi gav PYY3-36 and PYY1-36 intravenöst (direkt i blodet) till friska 
försökspersoner, samtidigt som de fick inta en fast måltid, förlängdes 
magsäckstömningen och insulinnivån i blodet höjdes. Mättnadskänslan påverkades inte 
men däremot kunde PYY3-36 inducera illamående och försökspersonerna fick mindre 
lust att äta. Eftersom många FD patienter lider av illamående och oftast äter för lite, 
skulle det vara värdefullt att närmare kartlägga vilken roll PYY3-36 har i utvecklingen 
av dessa symptom.  
 
Vi undersökte GLP-1 närmare genom att hämma dess receptor (mottagare). Man har 
tidigare gjort försök där GLP-1 gavs direkt i blodet, men det finns inte många studier 
som fokuserat på funktionen av kroppseget GLP-1 i samband med måltid. Våra resultat 
visade att kroppseget GLP-1 effektivt och oberoende av matintag hämmar en substans 
som heter glukagon och som är mycket viktig i blodsockerregleringen. Det framkom 
även att kroppseget GLP-1 modulerar insulinnivåer i blodet efter måltid och kan ändra 
magsäckens rörelsemönster utan att hämma tömningshastigheten. Mättnadskänslan 
 
 
 
 
 
  
53  
påverkades inte och försökspersonerna blev inte illamående av den GLP-1 hämmande 
substansen (vilket de oftast blir av GLP-1 när det ges intravenöst). Vi undersökte GLP-
1 närmare i FD patienter, genom att mäta GLP-1, insulin och glukosnivåer i blodet efter 
att patienterna (och friska kontroller) hade fått dricka näringslösning med en markör för 
mätning av magsäckstömning. FD patienter hade högre insulinnivåer efter måltid 
jämfört med kontrollpersonerna, samtidigt som blodsockernivåerna var normala. Detta 
gällde framförallt patienter med smärta som framträdande symptom. Patienterna 
uppgav i högre grad än kontrollpersonerna mättnadskänsla, illamående och smärta efter 
matintag, vilket vi inte kunde förklara med ändringar i magsäckens tömningshastighet. 
Att insulinnivåerna är annorlunda hos patienter med FD är nytt och bör undersökas 
närmare i framtida studier. Våra resultat talar även för att ett rörelsemönster i 
magsäckens olika delar kan vara viktigare i mekanism bakom FD än 
tömningshastigheten. GLP-1, liksom PYY3-36, verkar ha en funktion i uppkomsten av 
illamående.   
 
Det sker en livlig transport av olika ämnen mellan tarmen och blodet via 
tarmslemhinnan. När vi stimulerade slemhinnan med serotonin, kunde vi se att 
transporten för laddade ämnen är annorlunda hos FD patienter, sannolikt på grund av 
ökad bikarbonatutsöndring (ett ämne som neutraliserar och skyddar från frätande 
magsyra). I samma vävnad kunde vi kartlägga ändringar i genuttryck hos några av 
serotoninets olika receptorer. Vid utveckling av framtida läkemedel är det en fördel att 
veta vilka receptorer som är inblandade. Med hjälp av läkemedel som effektivt och 
specifikt hämmar eller aktiverar en av “nyckelreceptorerna” skulle man målinriktat 
kunna påverka de mekanismer som ger upphov till symptom. Baserat på våra resultat 
rekommenderas fler studier kring rollen hos serotoninreceptorerna 3E och 7.  
 
FD patienter hade mindre antal celler som kan utsöndra signalämnen av olika slag i 
tolvfingertarmens slemhinna. Detta gällde specifikt patienter med smärta som 
framträdande symptom. När vi enbart färgade celler som innehöll serotonin, var antalet 
celler lika hos patienter och friska. FD patienter verkar alltså ha ett mindre antal celler 
som innehåller andra signalsubstanser än serotonin i tunntarmens slemhinna. Att färga 
dessa celler för PYY3-36 och GLP-1 blir därför ett intressant framtida 
forskningsprojekt .  
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